Details of the Drug Combinations

General Information of This Drug (ID: DMLYGH4)

Drug Name
MK-4827   DMLYGH4
Synonyms
1038915-60-4; (S)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide; UNII-HMC2H89N35; HMC2H89N35; CHEMBL1094636; 2-{4-[(3s)-piperidin-3-yl]phenyl}-2h-indazole-7-carboxamide; MK4827; MK 4827; Niraparib [USAN:INN]; 2-{4-[(3S)-piperidin-3-yl]phenyl}indazole-7-carboxamide; 2-[4-[(3S)-piperidin-3-yl]phenyl]indazole-7-carboxamide; MK 4827 (Base); Niraparib (USAN); Zejula (TN); MK-4827(Niraparib); SCHEMBL1421875; GTPL8275; CTK8B9123; EX-A290; DTXSID50146129; MolPort-023-219-142; ZINC43206370; BDBM50316226
Indication
Disease Entry ICD 11 Status REF
Ovarian cancer 2C73 Phase 3 [1]
Breast cancer 2C60-2C65 Phase 2 [2]
Ewing sarcoma 2B52 Phase 1 [2]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

893 Investigative Drug Combination(s) Consisting of This drug
Normalized Drug Combination Synergy Score
Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
DrugCom Name DrugCom ID Component Drug Indication REF
Bortezomib + MK-4827 DCZ7PRA Bortezomib Adenocarcinoma (Cell Line: CAOV3) [3]
Bortezomib + MK-4827 DCBEMGI Bortezomib Adenocarcinoma (Cell Line: OVCAR3) [3]
Bortezomib + MK-4827 DCXG1XH Bortezomib Adenocarcinoma (Cell Line: NCIH2122) [3]
Bortezomib + MK-4827 DC2KTZ8 Bortezomib Adenocarcinoma (Cell Line: NCIH23) [3]
Bortezomib + MK-4827 DCXLGL9 Bortezomib Adenocarcinoma (Cell Line: NCIH520) [3]
Bortezomib + MK-4827 DC9UUY5 Bortezomib Adenocarcinoma (Cell Line: COLO320DM) [3]
Bortezomib + MK-4827 DCTG1E3 Bortezomib Adenocarcinoma (Cell Line: SW-620) [3]
Bortezomib + MK-4827 DCWGFDK Bortezomib Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
Bortezomib + MK-4827 DCSM0Q6 Bortezomib Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Bortezomib + MK-4827 DC1MOB9 Bortezomib Malignant melanoma (Cell Line: RPMI7951) [3]
Bortezomib + MK-4827 DC7PA1E Bortezomib Mesothelioma (Cell Line: MSTO) [3]
Bortezomib + MK-4827 DCYID6P Bortezomib Non small cell carcinoma (Cell Line: SKMES1) [3]
Bortezomib + MK-4827 DCM8IQH Bortezomib Prostate carcinoma (Cell Line: LNCAP) [3]
Bortezomib + MK-4827 DC2TGAA Bortezomib Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
Bortezomib + MK-4827 DCG57DL Bortezomib Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
Bortezomib + MK-4827 DC0AGCJ Bortezomib Breast carcinoma (Cell Line: ZR751) [4]
Bortezomib + MK-4827 DC3R9L4 Bortezomib Breast carcinoma (Cell Line: KPL1) [4]
Bortezomib + MK-4827 DCFCVHI Bortezomib Breast carcinoma (Cell Line: OCUBM) [4]
Bortezomib + MK-4827 DCN1GAR Bortezomib Carcinoma (Cell Line: OV90) [4]
Bortezomib + MK-4827 DCT2OFU Bortezomib Carcinoma (Cell Line: EFM192B) [4]
Bortezomib + MK-4827 DC333HS Bortezomib Colon adenocarcinoma (Cell Line: LOVO) [4]
Bortezomib + MK-4827 DCJL3TB Bortezomib Invasive ductal carcinoma (Cell Line: T-47D) [4]
Bortezomib + MK-4827 DCYVMM0 Bortezomib Rectal adenocarcinoma (Cell Line: SW837) [4]
Cyclophosphamide + MK-4827 DC2Z6AF Cyclophosphamide Adenocarcinoma (Cell Line: NCIH2122) [3]
Cyclophosphamide + MK-4827 DC0Q2FE Cyclophosphamide Adenocarcinoma (Cell Line: COLO320DM) [3]
Cyclophosphamide + MK-4827 DCZT0MV Cyclophosphamide Adenocarcinoma (Cell Line: DLD1) [3]
Cyclophosphamide + MK-4827 DCX9SO9 Cyclophosphamide Adenocarcinoma (Cell Line: HCT116) [3]
Cyclophosphamide + MK-4827 DCWJRIV Cyclophosphamide Malignant melanoma (Cell Line: A375) [3]
Cyclophosphamide + MK-4827 DCL4QID Cyclophosphamide Malignant melanoma (Cell Line: RPMI7951) [3]
Cyclophosphamide + MK-4827 DCSH8PT Cyclophosphamide Malignant melanoma (Cell Line: SKMEL30) [3]
Cyclophosphamide + MK-4827 DCOYS1O Cyclophosphamide Non small cell carcinoma (Cell Line: SKMES1) [3]
Cyclophosphamide + MK-4827 DCFMAJ3 Cyclophosphamide Colon carcinoma (Cell Line: RKO) [4]
Dasatinib + MK-4827 DCHC0JC Dasatinib Adenocarcinoma (Cell Line: CAOV3) [3]
Dasatinib + MK-4827 DCA3INL Dasatinib Adenocarcinoma (Cell Line: OVCAR3) [3]
Dasatinib + MK-4827 DC71ZOK Dasatinib Adenocarcinoma (Cell Line: A427) [3]
Dasatinib + MK-4827 DC2OKE7 Dasatinib Adenocarcinoma (Cell Line: NCIH1650) [3]
Dasatinib + MK-4827 DCQZGOQ Dasatinib Adenocarcinoma (Cell Line: NCIH23) [3]
Dasatinib + MK-4827 DC7IWC1 Dasatinib Adenocarcinoma (Cell Line: NCIH520) [3]
Dasatinib + MK-4827 DCDK6WE Dasatinib Adenocarcinoma (Cell Line: COLO320DM) [3]
Dasatinib + MK-4827 DC6RTRN Dasatinib Adenocarcinoma (Cell Line: DLD1) [3]
Dasatinib + MK-4827 DC8BOWZ Dasatinib Adenocarcinoma (Cell Line: HCT116) [3]
Dasatinib + MK-4827 DCNGNT5 Dasatinib Adenocarcinoma (Cell Line: HT29) [3]
Dasatinib + MK-4827 DCQEH0Q Dasatinib Adenocarcinoma (Cell Line: SW-620) [3]
Dasatinib + MK-4827 DCBYIDT Dasatinib Amelanotic melanoma (Cell Line: A2058) [3]
Dasatinib + MK-4827 DC4HWYV Dasatinib Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
Dasatinib + MK-4827 DC2ONGT Dasatinib Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Dasatinib + MK-4827 DC2IELE Dasatinib Malignant melanoma (Cell Line: A375) [3]
Dasatinib + MK-4827 DCRYUOU Dasatinib Malignant melanoma (Cell Line: SKMEL30) [3]
Dasatinib + MK-4827 DCEURGT Dasatinib Mesothelioma (Cell Line: MSTO) [3]
Dasatinib + MK-4827 DCJ79HU Dasatinib Non small cell carcinoma (Cell Line: SKMES1) [3]
Dasatinib + MK-4827 DC75F21 Dasatinib Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [3]
Dasatinib + MK-4827 DC2RTVB Dasatinib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
Dasatinib + MK-4827 DCGKMMY Dasatinib Prostate carcinoma (Cell Line: LNCAP) [3]
Dasatinib + MK-4827 DC1JYPP Dasatinib Prostate carcinoma (Cell Line: VCAP) [3]
Dasatinib + MK-4827 DC41GQP Dasatinib Breast carcinoma (Cell Line: KPL1) [4]
Dasatinib + MK-4827 DCHTIDL Dasatinib Breast carcinoma (Cell Line: OCUBM) [4]
Dasatinib + MK-4827 DCM8WTD Dasatinib Carcinoma (Cell Line: OV90) [4]
Dasatinib + MK-4827 DCUFPQ9 Dasatinib Carcinoma (Cell Line: EFM192B) [4]
Dasatinib + MK-4827 DCTGVJV Dasatinib Carcinoma (Cell Line: MDAMB436) [4]
Dasatinib + MK-4827 DCRJ9Z6 Dasatinib Colon carcinoma (Cell Line: RKO) [4]
Dasatinib + MK-4827 DCW9IHJ Dasatinib Invasive ductal carcinoma (Cell Line: T-47D) [4]
Dasatinib + MK-4827 DCPHZAA Dasatinib Rectal adenocarcinoma (Cell Line: SW837) [4]
Dexamethasone + MK-4827 DC1VFXJ Dexamethasone Breast carcinoma (Cell Line: KPL1) [4]
Dexamethasone + MK-4827 DCOFOQN Dexamethasone Colon adenocarcinoma (Cell Line: LOVO) [4]
Dexamethasone + MK-4827 DCMNRKP Dexamethasone Colon carcinoma (Cell Line: RKO) [4]
Dexamethasone + MK-4827 DCNH5AF Dexamethasone Rectal adenocarcinoma (Cell Line: SW837) [4]
Dexamethasone + MK-4827 DC1TL9N Dexamethasone Adenocarcinoma (Cell Line: CAOV3) [5]
Dexamethasone + MK-4827 DCV0P5Q Dexamethasone Adenocarcinoma (Cell Line: NCIH2122) [5]
Dexamethasone + MK-4827 DCC74UJ Dexamethasone Adenocarcinoma (Cell Line: COLO320DM) [5]
Dexamethasone + MK-4827 DCNBUQE Dexamethasone Adenocarcinoma (Cell Line: DLD1) [5]
Dexamethasone + MK-4827 DC61OFO Dexamethasone Adenocarcinoma (Cell Line: HCT116) [5]
Dexamethasone + MK-4827 DC8DMA4 Dexamethasone Malignant melanoma (Cell Line: A375) [5]
Dexamethasone + MK-4827 DC11AG5 Dexamethasone Malignant melanoma (Cell Line: SKMEL30) [5]
Dexamethasone + MK-4827 DCTMZKH Dexamethasone Non small cell carcinoma (Cell Line: SKMES1) [5]
Dexamethasone + MK-4827 DCR9A1J Dexamethasone Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Doxorubicin + MK-4827 DCRGB95 Doxorubicin Adenocarcinoma (Cell Line: CAOV3) [3]
Doxorubicin + MK-4827 DCOMWBQ Doxorubicin Adenocarcinoma (Cell Line: A427) [3]
Doxorubicin + MK-4827 DCQQNWT Doxorubicin Adenocarcinoma (Cell Line: NCIH1650) [3]
Doxorubicin + MK-4827 DC9UG3A Doxorubicin Adenocarcinoma (Cell Line: NCIH520) [3]
Doxorubicin + MK-4827 DCI35U2 Doxorubicin Adenocarcinoma (Cell Line: COLO320DM) [3]
Doxorubicin + MK-4827 DCZSZU1 Doxorubicin Adenocarcinoma (Cell Line: DLD1) [3]
Doxorubicin + MK-4827 DCATWSC Doxorubicin Adenocarcinoma (Cell Line: HT29) [3]
Doxorubicin + MK-4827 DCVIH8G Doxorubicin Adenocarcinoma (Cell Line: SW-620) [3]
Doxorubicin + MK-4827 DCHFJ3S Doxorubicin Germ cell tumour (Cell Line: PA1) [3]
Doxorubicin + MK-4827 DCZ15QI Doxorubicin Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Doxorubicin + MK-4827 DCRJXWQ Doxorubicin Malignant melanoma (Cell Line: A375) [3]
Doxorubicin + MK-4827 DCMVI08 Doxorubicin Malignant melanoma (Cell Line: HT144) [3]
Doxorubicin + MK-4827 DCUBP8K Doxorubicin Malignant melanoma (Cell Line: SKMEL30) [3]
Doxorubicin + MK-4827 DCZLRWQ Doxorubicin Mesothelioma (Cell Line: MSTO) [3]
Doxorubicin + MK-4827 DCU9CZC Doxorubicin Non small cell carcinoma (Cell Line: SKMES1) [3]
Doxorubicin + MK-4827 DCXDLIS Doxorubicin Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [3]
Doxorubicin + MK-4827 DCRH8TS Doxorubicin Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
Doxorubicin + MK-4827 DCYIV0Q Doxorubicin Prostate carcinoma (Cell Line: LNCAP) [3]
Doxorubicin + MK-4827 DC4GMC5 Doxorubicin Prostate carcinoma (Cell Line: VCAP) [3]
Doxorubicin + MK-4827 DCTYHPR Doxorubicin Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
Doxorubicin + MK-4827 DCVEGLJ Doxorubicin Breast carcinoma (Cell Line: ZR751) [4]
Doxorubicin + MK-4827 DC8H7CJ Doxorubicin Breast carcinoma (Cell Line: KPL1) [4]
Doxorubicin + MK-4827 DCS0V2H Doxorubicin Breast carcinoma (Cell Line: OCUBM) [4]
Doxorubicin + MK-4827 DCMJ1DT Doxorubicin Carcinoma (Cell Line: EFM192B) [4]
Doxorubicin + MK-4827 DCT8G89 Doxorubicin Colon carcinoma (Cell Line: RKO) [4]
Doxorubicin + MK-4827 DC30CBW Doxorubicin Invasive ductal carcinoma (Cell Line: T-47D) [4]
Doxorubicin + MK-4827 DCBJWXJ Doxorubicin Rectal adenocarcinoma (Cell Line: SW837) [4]
Erlotinib + MK-4827 DC03QIJ Erlotinib Adenocarcinoma (Cell Line: CAOV3) [3]
Erlotinib + MK-4827 DCGH1IE Erlotinib Adenocarcinoma (Cell Line: OVCAR3) [3]
Erlotinib + MK-4827 DCJMO4P Erlotinib Adenocarcinoma (Cell Line: A427) [3]
Erlotinib + MK-4827 DCUH9VF Erlotinib Adenocarcinoma (Cell Line: NCIH2122) [3]
Erlotinib + MK-4827 DC19XR0 Erlotinib Adenocarcinoma (Cell Line: NCIH23) [3]
Erlotinib + MK-4827 DCG54VV Erlotinib Adenocarcinoma (Cell Line: NCIH520) [3]
Erlotinib + MK-4827 DC5Y81L Erlotinib Adenocarcinoma (Cell Line: COLO320DM) [3]
Erlotinib + MK-4827 DCL2ANL Erlotinib Adenocarcinoma (Cell Line: DLD1) [3]
Erlotinib + MK-4827 DCJTYT7 Erlotinib Adenocarcinoma (Cell Line: HCT116) [3]
Erlotinib + MK-4827 DC0W83Z Erlotinib Adenocarcinoma (Cell Line: HT29) [3]
Erlotinib + MK-4827 DC5FCN9 Erlotinib Adenocarcinoma (Cell Line: SW-620) [3]
Erlotinib + MK-4827 DCN9VS2 Erlotinib Amelanotic melanoma (Cell Line: A2058) [3]
Erlotinib + MK-4827 DCM6AE4 Erlotinib Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
Erlotinib + MK-4827 DCH02J5 Erlotinib Germ cell tumour (Cell Line: PA1) [3]
Erlotinib + MK-4827 DC0VV6K Erlotinib Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Erlotinib + MK-4827 DCHEDY8 Erlotinib Malignant melanoma (Cell Line: A375) [3]
Erlotinib + MK-4827 DC3POQE Erlotinib Malignant melanoma (Cell Line: HT144) [3]
Erlotinib + MK-4827 DCG0M5A Erlotinib Malignant melanoma (Cell Line: RPMI7951) [3]
Erlotinib + MK-4827 DCZ8NAS Erlotinib Malignant melanoma (Cell Line: SKMEL30) [3]
Erlotinib + MK-4827 DCTFYGE Erlotinib Malignant melanoma (Cell Line: UACC62) [3]
Erlotinib + MK-4827 DC4R5XF Erlotinib Non small cell carcinoma (Cell Line: SKMES1) [3]
Erlotinib + MK-4827 DC011UA Erlotinib Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [3]
Erlotinib + MK-4827 DCVUA20 Erlotinib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
Erlotinib + MK-4827 DC98K69 Erlotinib Prostate carcinoma (Cell Line: LNCAP) [3]
Erlotinib + MK-4827 DCG60RJ Erlotinib Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
Erlotinib + MK-4827 DCKE86M Erlotinib Breast carcinoma (Cell Line: KPL1) [4]
Erlotinib + MK-4827 DCWNPQ6 Erlotinib Breast carcinoma (Cell Line: OCUBM) [4]
Erlotinib + MK-4827 DCXXSJO Erlotinib Carcinoma (Cell Line: OV90) [4]
Erlotinib + MK-4827 DC3VAAH Erlotinib Carcinoma (Cell Line: EFM192B) [4]
Erlotinib + MK-4827 DCZANBO Erlotinib Colon adenocarcinoma (Cell Line: LOVO) [4]
Erlotinib + MK-4827 DCGQRYB Erlotinib Colon carcinoma (Cell Line: RKO) [4]
Erlotinib + MK-4827 DCLC4QF Erlotinib Invasive ductal carcinoma (Cell Line: T-47D) [4]
Erlotinib + MK-4827 DCNS45Z Erlotinib Rectal adenocarcinoma (Cell Line: SW837) [4]
Estramustine + MK-4827 DCCQWD8 Estramustine Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
Estramustine + MK-4827 DCVDU6R Estramustine Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
Estramustine + MK-4827 DC6QP93 Estramustine Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
Estramustine + MK-4827 DCSBN29 Estramustine Breast carcinoma (Cell Line: OCUBM) [4]
Estramustine + MK-4827 DC5PXLZ Estramustine Carcinoma (Cell Line: EFM192B) [4]
Estramustine + MK-4827 DCHGZDS Estramustine Carcinoma (Cell Line: MDAMB436) [4]
Estramustine + MK-4827 DCMQAS5 Estramustine Colon adenocarcinoma (Cell Line: LOVO) [4]
Estramustine + MK-4827 DCBTL6K Estramustine Colon carcinoma (Cell Line: RKO) [4]
Estramustine + MK-4827 DC44DUE Estramustine Rectal adenocarcinoma (Cell Line: SW837) [4]
Estramustine + MK-4827 DCFQCRE Estramustine Adenocarcinoma (Cell Line: CAOV3) [5]
Estramustine + MK-4827 DC5B0CG Estramustine Adenocarcinoma (Cell Line: A427) [5]
Estramustine + MK-4827 DCGOSKE Estramustine Adenocarcinoma (Cell Line: NCIH1650) [5]
Estramustine + MK-4827 DCXQNEO Estramustine Adenocarcinoma (Cell Line: NCIH2122) [5]
Estramustine + MK-4827 DC9PTV3 Estramustine Adenocarcinoma (Cell Line: NCIH23) [5]
Estramustine + MK-4827 DCWEHI9 Estramustine Adenocarcinoma (Cell Line: NCIH520) [5]
Estramustine + MK-4827 DC3WP0U Estramustine Adenocarcinoma (Cell Line: COLO320DM) [5]
Estramustine + MK-4827 DCMEYC8 Estramustine Adenocarcinoma (Cell Line: DLD1) [5]
Estramustine + MK-4827 DCSUO6D Estramustine Adenocarcinoma (Cell Line: HCT116) [5]
Estramustine + MK-4827 DCEJDAW Estramustine Adenocarcinoma (Cell Line: HT29) [5]
Estramustine + MK-4827 DCNCC3T Estramustine Adenocarcinoma (Cell Line: SW-620) [5]
Estramustine + MK-4827 DC3CSQQ Estramustine Amelanotic melanoma (Cell Line: A2058) [5]
Estramustine + MK-4827 DC4R6GG Estramustine Germ cell tumour (Cell Line: PA1) [5]
Estramustine + MK-4827 DCFNRK6 Estramustine Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Estramustine + MK-4827 DCPS87M Estramustine Malignant melanoma (Cell Line: A375) [5]
Estramustine + MK-4827 DC806PV Estramustine Malignant melanoma (Cell Line: RPMI7951) [5]
Estramustine + MK-4827 DCURHSP Estramustine Malignant melanoma (Cell Line: SKMEL30) [5]
Estramustine + MK-4827 DC8KZKY Estramustine Malignant melanoma (Cell Line: UACC62) [5]
Estramustine + MK-4827 DCRQ1ZE Estramustine Mesothelioma (Cell Line: MSTO) [5]
Estramustine + MK-4827 DC3QHQH Estramustine Non small cell carcinoma (Cell Line: SKMES1) [5]
Estramustine + MK-4827 DCB5BI2 Estramustine Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
Estramustine + MK-4827 DC2EAWX Estramustine Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Estramustine + MK-4827 DC1VSSS Estramustine Prostate carcinoma (Cell Line: LNCAP) [5]
Estramustine + MK-4827 DCN438M Estramustine Prostate carcinoma (Cell Line: VCAP) [5]
Etoposide + MK-4827 DCGF74C Etoposide Adenocarcinoma (Cell Line: CAOV3) [3]
Etoposide + MK-4827 DC0U5JR Etoposide Adenocarcinoma (Cell Line: A427) [3]
Etoposide + MK-4827 DCS3W2X Etoposide Adenocarcinoma (Cell Line: NCIH1650) [3]
Etoposide + MK-4827 DC3XMI8 Etoposide Adenocarcinoma (Cell Line: NCIH2122) [3]
Etoposide + MK-4827 DC69KFQ Etoposide Adenocarcinoma (Cell Line: COLO320DM) [3]
Etoposide + MK-4827 DCJQT6O Etoposide Adenocarcinoma (Cell Line: HCT116) [3]
Etoposide + MK-4827 DC9JCGH Etoposide Adenocarcinoma (Cell Line: HT29) [3]
Etoposide + MK-4827 DCE2H04 Etoposide Adenocarcinoma (Cell Line: SW-620) [3]
Etoposide + MK-4827 DCLBMJY Etoposide Amelanotic melanoma (Cell Line: A2058) [3]
Etoposide + MK-4827 DC4N4B2 Etoposide Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
Etoposide + MK-4827 DCV0LOA Etoposide Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Etoposide + MK-4827 DCO8PVZ Etoposide Malignant melanoma (Cell Line: A375) [3]
Etoposide + MK-4827 DCZ9IL7 Etoposide Malignant melanoma (Cell Line: HT144) [3]
Etoposide + MK-4827 DCX9256 Etoposide Malignant melanoma (Cell Line: SKMEL30) [3]
Etoposide + MK-4827 DCEXRDJ Etoposide Malignant melanoma (Cell Line: UACC62) [3]
Etoposide + MK-4827 DCHCVDJ Etoposide Mesothelioma (Cell Line: MSTO) [3]
Etoposide + MK-4827 DCFDAH9 Etoposide Non small cell carcinoma (Cell Line: SKMES1) [3]
Etoposide + MK-4827 DCXB48K Etoposide Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [3]
Etoposide + MK-4827 DC5HQEH Etoposide Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
Etoposide + MK-4827 DCIUIZG Etoposide Prostate carcinoma (Cell Line: LNCAP) [3]
Etoposide + MK-4827 DCEXNVT Etoposide Prostate carcinoma (Cell Line: VCAP) [3]
Etoposide + MK-4827 DC81M3J Etoposide Breast carcinoma (Cell Line: KPL1) [4]
Etoposide + MK-4827 DCUIRW8 Etoposide Breast carcinoma (Cell Line: OCUBM) [4]
Etoposide + MK-4827 DCMDRDC Etoposide Carcinoma (Cell Line: EFM192B) [4]
Etoposide + MK-4827 DCAE54V Etoposide Carcinoma (Cell Line: MDAMB436) [4]
Etoposide + MK-4827 DCRW5SE Etoposide Colon carcinoma (Cell Line: RKO) [4]
Etoposide + MK-4827 DCGWLCK Etoposide Invasive ductal carcinoma (Cell Line: T-47D) [4]
Etoposide + MK-4827 DCI4KM8 Etoposide Rectal adenocarcinoma (Cell Line: SW837) [4]
Fluorouracil + MK-4827 DCH1B10 Fluorouracil Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
Fluorouracil + MK-4827 DCG10K0 Fluorouracil Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
Fluorouracil + MK-4827 DCOSN5K Fluorouracil Breast carcinoma (Cell Line: KPL1) [4]
Fluorouracil + MK-4827 DC05P9A Fluorouracil Breast carcinoma (Cell Line: OCUBM) [4]
Fluorouracil + MK-4827 DCNWE86 Fluorouracil Carcinoma (Cell Line: OV90) [4]
Fluorouracil + MK-4827 DCZEIZS Fluorouracil Carcinoma (Cell Line: EFM192B) [4]
Fluorouracil + MK-4827 DC07NMT Fluorouracil Carcinoma (Cell Line: MDAMB436) [4]
Fluorouracil + MK-4827 DCT785J Fluorouracil Colon adenocarcinoma (Cell Line: LOVO) [4]
Fluorouracil + MK-4827 DC6DV7S Fluorouracil Colon carcinoma (Cell Line: RKO) [4]
Fluorouracil + MK-4827 DC9OP8K Fluorouracil Invasive ductal carcinoma (Cell Line: T-47D) [4]
Fluorouracil + MK-4827 DCH4LI2 Fluorouracil Rectal adenocarcinoma (Cell Line: SW837) [4]
Fluorouracil + MK-4827 DCX6MDG Fluorouracil Adenocarcinoma (Cell Line: CAOV3) [5]
Fluorouracil + MK-4827 DCGDNQX Fluorouracil Adenocarcinoma (Cell Line: OVCAR3) [5]
Fluorouracil + MK-4827 DCV8TUR Fluorouracil Adenocarcinoma (Cell Line: A427) [5]
Fluorouracil + MK-4827 DCWJWNP Fluorouracil Adenocarcinoma (Cell Line: NCIH1650) [5]
Fluorouracil + MK-4827 DC65EO8 Fluorouracil Adenocarcinoma (Cell Line: NCIH2122) [5]
Fluorouracil + MK-4827 DCMUOLT Fluorouracil Adenocarcinoma (Cell Line: NCIH23) [5]
Fluorouracil + MK-4827 DCW4TYL Fluorouracil Adenocarcinoma (Cell Line: NCIH520) [5]
Fluorouracil + MK-4827 DCBQXAQ Fluorouracil Adenocarcinoma (Cell Line: COLO320DM) [5]
Fluorouracil + MK-4827 DCYZMU9 Fluorouracil Adenocarcinoma (Cell Line: DLD1) [5]
Fluorouracil + MK-4827 DCBJNI9 Fluorouracil Adenocarcinoma (Cell Line: HCT116) [5]
Fluorouracil + MK-4827 DCJKJF3 Fluorouracil Adenocarcinoma (Cell Line: HT29) [5]
Fluorouracil + MK-4827 DCQ4ON8 Fluorouracil Amelanotic melanoma (Cell Line: A2058) [5]
Fluorouracil + MK-4827 DC8EEN4 Fluorouracil Germ cell tumour (Cell Line: PA1) [5]
Fluorouracil + MK-4827 DCVSPF4 Fluorouracil Malignant melanoma (Cell Line: A375) [5]
Fluorouracil + MK-4827 DCLNK6P Fluorouracil Malignant melanoma (Cell Line: RPMI7951) [5]
Fluorouracil + MK-4827 DC1I1I5 Fluorouracil Malignant melanoma (Cell Line: SKMEL30) [5]
Fluorouracil + MK-4827 DCS82RE Fluorouracil Mesothelioma (Cell Line: MSTO) [5]
Fluorouracil + MK-4827 DC5MO8P Fluorouracil Non small cell carcinoma (Cell Line: SKMES1) [5]
Fluorouracil + MK-4827 DCC1TVY Fluorouracil Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
Fluorouracil + MK-4827 DCXM7SC Fluorouracil Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Fluorouracil + MK-4827 DCJMN6N Fluorouracil Prostate carcinoma (Cell Line: LNCAP) [5]
Fluorouracil + MK-4827 DCFMZ2J Fluorouracil Prostate carcinoma (Cell Line: VCAP) [5]
Gemcitabine + MK-4827 DCIO9JF Gemcitabine Adenocarcinoma (Cell Line: A427) [3]
Gemcitabine + MK-4827 DC0N87Y Gemcitabine Adenocarcinoma (Cell Line: NCIH2122) [3]
Gemcitabine + MK-4827 DC3VU2U Gemcitabine Adenocarcinoma (Cell Line: NCIH520) [3]
Gemcitabine + MK-4827 DC9DXKQ Gemcitabine Adenocarcinoma (Cell Line: COLO320DM) [3]
Gemcitabine + MK-4827 DC3W4FP Gemcitabine Adenocarcinoma (Cell Line: DLD1) [3]
Gemcitabine + MK-4827 DCU4H8B Gemcitabine Adenocarcinoma (Cell Line: HT29) [3]
Gemcitabine + MK-4827 DCUX19P Gemcitabine Adenocarcinoma (Cell Line: SW-620) [3]
Gemcitabine + MK-4827 DCYWJ6D Gemcitabine Amelanotic melanoma (Cell Line: A2058) [3]
Gemcitabine + MK-4827 DCM241T Gemcitabine Germ cell tumour (Cell Line: PA1) [3]
Gemcitabine + MK-4827 DCDNWTF Gemcitabine Malignant melanoma (Cell Line: A375) [3]
Gemcitabine + MK-4827 DCJC2GY Gemcitabine Malignant melanoma (Cell Line: HT144) [3]
Gemcitabine + MK-4827 DCKPL66 Gemcitabine Malignant melanoma (Cell Line: RPMI7951) [3]
Gemcitabine + MK-4827 DCSWY0M Gemcitabine Malignant melanoma (Cell Line: SKMEL30) [3]
Gemcitabine + MK-4827 DC82FHN Gemcitabine Malignant melanoma (Cell Line: UACC62) [3]
Gemcitabine + MK-4827 DCJ2V12 Gemcitabine Mesothelioma (Cell Line: MSTO) [3]
Gemcitabine + MK-4827 DC3D3EC Gemcitabine Non small cell carcinoma (Cell Line: SKMES1) [3]
Gemcitabine + MK-4827 DCPT2PP Gemcitabine Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [3]
Gemcitabine + MK-4827 DCNQMX3 Gemcitabine Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
Gemcitabine + MK-4827 DCFBC8F Gemcitabine Prostate carcinoma (Cell Line: VCAP) [3]
Gemcitabine + MK-4827 DCIO9VN Gemcitabine Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
Gemcitabine + MK-4827 DCPM4HL Gemcitabine Breast carcinoma (Cell Line: KPL1) [4]
Gemcitabine + MK-4827 DCDYA05 Gemcitabine Breast carcinoma (Cell Line: OCUBM) [4]
Gemcitabine + MK-4827 DCIKB66 Gemcitabine Carcinoma (Cell Line: EFM192B) [4]
Gemcitabine + MK-4827 DC9ELYV Gemcitabine Carcinoma (Cell Line: MDAMB436) [4]
Gemcitabine + MK-4827 DCW9446 Gemcitabine Colon carcinoma (Cell Line: RKO) [4]
Gemcitabine + MK-4827 DCV2RIU Gemcitabine Invasive ductal carcinoma (Cell Line: T-47D) [4]
GSK525762 + MK-4827 DCW32E6 GSK525762 Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
GSK525762 + MK-4827 DCLO6BN GSK525762 Breast carcinoma (Cell Line: KPL1) [4]
GSK525762 + MK-4827 DCNL1QJ GSK525762 Adenocarcinoma (Cell Line: OVCAR3) [5]
GSK525762 + MK-4827 DCOAV7N GSK525762 Adenocarcinoma (Cell Line: NCIH2122) [5]
GSK525762 + MK-4827 DCEGI4M GSK525762 Mesothelioma (Cell Line: MSTO) [5]
GSK525762 + MK-4827 DCJJ0YW GSK525762 Non small cell carcinoma (Cell Line: SKMES1) [5]
Idarubicin + MK-4827 DCC2OUV Idarubicin Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
Idarubicin + MK-4827 DC5B4AY Idarubicin Carcinoma (Cell Line: MDAMB436) [4]
Idarubicin + MK-4827 DCSIZOX Idarubicin Colon carcinoma (Cell Line: RKO) [4]
Idarubicin + MK-4827 DCMQESX Idarubicin Adenocarcinoma (Cell Line: A427) [5]
Idarubicin + MK-4827 DCHWG2F Idarubicin Adenocarcinoma (Cell Line: NCIH2122) [5]
Idarubicin + MK-4827 DCJFV7N Idarubicin Adenocarcinoma (Cell Line: NCIH23) [5]
Idarubicin + MK-4827 DCETASI Idarubicin Adenocarcinoma (Cell Line: COLO320DM) [5]
Idarubicin + MK-4827 DCVCNGI Idarubicin Adenocarcinoma (Cell Line: HCT116) [5]
Idarubicin + MK-4827 DCXX7J4 Idarubicin Adenocarcinoma (Cell Line: SW-620) [5]
Idarubicin + MK-4827 DC27IAU Idarubicin Amelanotic melanoma (Cell Line: A2058) [5]
Idarubicin + MK-4827 DCTGFDP Idarubicin Germ cell tumour (Cell Line: PA1) [5]
Idarubicin + MK-4827 DCSSAKR Idarubicin Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Idarubicin + MK-4827 DCT6D17 Idarubicin Malignant melanoma (Cell Line: HT144) [5]
Idarubicin + MK-4827 DCXL7YD Idarubicin Malignant melanoma (Cell Line: RPMI7951) [5]
Idarubicin + MK-4827 DCRACVR Idarubicin Malignant melanoma (Cell Line: SKMEL30) [5]
Idarubicin + MK-4827 DCDXBEC Idarubicin Malignant melanoma (Cell Line: UACC62) [5]
Idarubicin + MK-4827 DC1SS8O Idarubicin Malignant melanoma (Cell Line: A375) [5]
Idarubicin + MK-4827 DC6CUKI Idarubicin Mesothelioma (Cell Line: MSTO) [5]
Idarubicin + MK-4827 DC4SIYG Idarubicin Non small cell carcinoma (Cell Line: SKMES1) [5]
Idarubicin + MK-4827 DC9TFEC Idarubicin Prostate carcinoma (Cell Line: VCAP) [5]
Lapatinib + MK-4827 DCG9MUY Lapatinib Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
Lapatinib + MK-4827 DCROE3V Lapatinib Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
Lapatinib + MK-4827 DCS3PIE Lapatinib Breast carcinoma (Cell Line: KPL1) [4]
Lapatinib + MK-4827 DCMC3RW Lapatinib Breast carcinoma (Cell Line: OCUBM) [4]
Lapatinib + MK-4827 DCC07FH Lapatinib Carcinoma (Cell Line: OV90) [4]
Lapatinib + MK-4827 DCSS3E4 Lapatinib Carcinoma (Cell Line: EFM192B) [4]
Lapatinib + MK-4827 DCZWCW6 Lapatinib Colon adenocarcinoma (Cell Line: LOVO) [4]
Lapatinib + MK-4827 DCQNGK7 Lapatinib Colon carcinoma (Cell Line: RKO) [4]
Lapatinib + MK-4827 DCBFK0L Lapatinib Invasive ductal carcinoma (Cell Line: T-47D) [4]
Lapatinib + MK-4827 DCNZHJ5 Lapatinib Rectal adenocarcinoma (Cell Line: SW837) [4]
Lapatinib + MK-4827 DCNMQNC Lapatinib Adenocarcinoma (Cell Line: CAOV3) [5]
Lapatinib + MK-4827 DCAZA14 Lapatinib Adenocarcinoma (Cell Line: NCIH1650) [5]
Lapatinib + MK-4827 DCLVQU1 Lapatinib Adenocarcinoma (Cell Line: NCIH2122) [5]
Lapatinib + MK-4827 DCFKPCB Lapatinib Adenocarcinoma (Cell Line: NCIH23) [5]
Lapatinib + MK-4827 DC3IXI9 Lapatinib Adenocarcinoma (Cell Line: NCIH520) [5]
Lapatinib + MK-4827 DCX15U6 Lapatinib Adenocarcinoma (Cell Line: COLO320DM) [5]
Lapatinib + MK-4827 DCKUVAX Lapatinib Adenocarcinoma (Cell Line: DLD1) [5]
Lapatinib + MK-4827 DC2AQMJ Lapatinib Adenocarcinoma (Cell Line: HT29) [5]
Lapatinib + MK-4827 DCOWG8P Lapatinib Amelanotic melanoma (Cell Line: A2058) [5]
Lapatinib + MK-4827 DC9OV8V Lapatinib Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [5]
Lapatinib + MK-4827 DC6L7M8 Lapatinib Germ cell tumour (Cell Line: PA1) [5]
Lapatinib + MK-4827 DCCY7Y1 Lapatinib Malignant melanoma (Cell Line: A375) [5]
Lapatinib + MK-4827 DCSTLKF Lapatinib Malignant melanoma (Cell Line: RPMI7951) [5]
Lapatinib + MK-4827 DCN46IZ Lapatinib Malignant melanoma (Cell Line: SKMEL30) [5]
Lapatinib + MK-4827 DC73KQ8 Lapatinib Malignant melanoma (Cell Line: UACC62) [5]
Lapatinib + MK-4827 DCBSVGB Lapatinib Mesothelioma (Cell Line: MSTO) [5]
Lapatinib + MK-4827 DCU36L0 Lapatinib Non small cell carcinoma (Cell Line: SKMES1) [5]
Lapatinib + MK-4827 DCAAYO9 Lapatinib Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
Lapatinib + MK-4827 DCDMYZK Lapatinib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Metformin + MK-4827 DC3QMWE Metformin Adenocarcinoma (Cell Line: NCIH1650) [3]
Metformin + MK-4827 DCJHU0K Metformin Adenocarcinoma (Cell Line: NCIH520) [3]
Metformin + MK-4827 DCIB4EE Metformin Adenocarcinoma (Cell Line: COLO320DM) [3]
Metformin + MK-4827 DC4RJJL Metformin Adenocarcinoma (Cell Line: HCT116) [3]
Metformin + MK-4827 DC5NYRE Metformin Adenocarcinoma (Cell Line: HT29) [3]
Metformin + MK-4827 DCVX14L Metformin Amelanotic melanoma (Cell Line: A2058) [3]
Metformin + MK-4827 DCV0NPE Metformin Malignant melanoma (Cell Line: SKMEL30) [3]
Metformin + MK-4827 DC0Y88K Metformin Non small cell carcinoma (Cell Line: SKMES1) [3]
Metformin + MK-4827 DCFXORH Metformin Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
Metformin + MK-4827 DCX0YG6 Metformin Breast carcinoma (Cell Line: OCUBM) [4]
Metformin + MK-4827 DCBNXOO Metformin Carcinoma (Cell Line: OV90) [4]
Methotrexate + MK-4827 DCB2VED Methotrexate Adenocarcinoma (Cell Line: A427) [3]
Methotrexate + MK-4827 DCLG5GR Methotrexate Adenocarcinoma (Cell Line: NCIH23) [3]
Methotrexate + MK-4827 DCECWHE Methotrexate Germ cell tumour (Cell Line: PA1) [3]
Methotrexate + MK-4827 DCGPNZR Methotrexate Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Methotrexate + MK-4827 DC3PP3V Methotrexate Malignant melanoma (Cell Line: HT144) [3]
Methotrexate + MK-4827 DCXIG3C Methotrexate Malignant melanoma (Cell Line: SKMEL30) [3]
Methotrexate + MK-4827 DCDUK5H Methotrexate Mesothelioma (Cell Line: MSTO) [3]
Methotrexate + MK-4827 DCTM1LT Methotrexate Carcinoma (Cell Line: EFM192B) [4]
Methotrexate + MK-4827 DCVUBB0 Methotrexate Rectal adenocarcinoma (Cell Line: SW837) [4]
Mitomycin + MK-4827 DCEJA4Z Mitomycin Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
Mitomycin + MK-4827 DCC21YY Mitomycin Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
Mitomycin + MK-4827 DCGI4KS Mitomycin Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
Mitomycin + MK-4827 DC6ZSD4 Mitomycin Breast carcinoma (Cell Line: KPL1) [4]
Mitomycin + MK-4827 DC5EIKS Mitomycin Breast carcinoma (Cell Line: OCUBM) [4]
Mitomycin + MK-4827 DCNMCS4 Mitomycin Carcinoma (Cell Line: EFM192B) [4]
Mitomycin + MK-4827 DC2KD4U Mitomycin Colon adenocarcinoma (Cell Line: LOVO) [4]
Mitomycin + MK-4827 DCG9WT3 Mitomycin Colon carcinoma (Cell Line: RKO) [4]
Mitomycin + MK-4827 DCAN8K3 Mitomycin Invasive ductal carcinoma (Cell Line: T-47D) [4]
Mitomycin + MK-4827 DC9DNKB Mitomycin Adenocarcinoma (Cell Line: CAOV3) [5]
Mitomycin + MK-4827 DCJ9WP9 Mitomycin Adenocarcinoma (Cell Line: A427) [5]
Mitomycin + MK-4827 DCA95HN Mitomycin Adenocarcinoma (Cell Line: NCIH1650) [5]
Mitomycin + MK-4827 DCW7RTJ Mitomycin Adenocarcinoma (Cell Line: NCIH2122) [5]
Mitomycin + MK-4827 DC03FZE Mitomycin Adenocarcinoma (Cell Line: NCIH23) [5]
Mitomycin + MK-4827 DCEAMXD Mitomycin Adenocarcinoma (Cell Line: COLO320DM) [5]
Mitomycin + MK-4827 DCPZS2L Mitomycin Adenocarcinoma (Cell Line: DLD1) [5]
Mitomycin + MK-4827 DCQXX3K Mitomycin Adenocarcinoma (Cell Line: HCT116) [5]
Mitomycin + MK-4827 DCAY2F1 Mitomycin Adenocarcinoma (Cell Line: HT29) [5]
Mitomycin + MK-4827 DCRWMKZ Mitomycin Adenocarcinoma (Cell Line: SW-620) [5]
Mitomycin + MK-4827 DC1513C Mitomycin Amelanotic melanoma (Cell Line: A2058) [5]
Mitomycin + MK-4827 DC336YK Mitomycin Germ cell tumour (Cell Line: PA1) [5]
Mitomycin + MK-4827 DCT0MHX Mitomycin Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Mitomycin + MK-4827 DC2TJSI Mitomycin Malignant melanoma (Cell Line: A375) [5]
Mitomycin + MK-4827 DCE7R7O Mitomycin Malignant melanoma (Cell Line: HT144) [5]
Mitomycin + MK-4827 DC16URR Mitomycin Malignant melanoma (Cell Line: SKMEL30) [5]
Mitomycin + MK-4827 DC9LH6A Mitomycin Malignant melanoma (Cell Line: UACC62) [5]
Mitomycin + MK-4827 DC49DOV Mitomycin Mesothelioma (Cell Line: MSTO) [5]
Mitomycin + MK-4827 DC4PM32 Mitomycin Non small cell carcinoma (Cell Line: SKMES1) [5]
Mitomycin + MK-4827 DCA9BSY Mitomycin Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
Mitomycin + MK-4827 DCWK6BD Mitomycin Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Mitomycin + MK-4827 DCTGNT5 Mitomycin Prostate carcinoma (Cell Line: VCAP) [5]
MK-1775 + MK-4827 DCS4AFH MK-1775 Adenocarcinoma (Cell Line: OVCAR3) [3]
MK-1775 + MK-4827 DCZJ0WT MK-1775 Adenocarcinoma (Cell Line: A427) [3]
MK-1775 + MK-4827 DCUOZ58 MK-1775 Adenocarcinoma (Cell Line: NCIH2122) [3]
MK-1775 + MK-4827 DCUXGOA MK-1775 Adenocarcinoma (Cell Line: NCIH23) [3]
MK-1775 + MK-4827 DCIAJFG MK-1775 Adenocarcinoma (Cell Line: NCIH520) [3]
MK-1775 + MK-4827 DC1H17C MK-1775 Adenocarcinoma (Cell Line: COLO320DM) [3]
MK-1775 + MK-4827 DCV06I1 MK-1775 Adenocarcinoma (Cell Line: HCT116) [3]
MK-1775 + MK-4827 DCQH4L2 MK-1775 Adenocarcinoma (Cell Line: HT29) [3]
MK-1775 + MK-4827 DCXKP27 MK-1775 Adenocarcinoma (Cell Line: SW-620) [3]
MK-1775 + MK-4827 DCB756T MK-1775 Amelanotic melanoma (Cell Line: A2058) [3]
MK-1775 + MK-4827 DC789LA MK-1775 Germ cell tumour (Cell Line: PA1) [3]
MK-1775 + MK-4827 DCOT6P6 MK-1775 Large cell lung carcinoma (Cell Line: NCI-H460) [3]
MK-1775 + MK-4827 DC1K916 MK-1775 Malignant melanoma (Cell Line: A375) [3]
MK-1775 + MK-4827 DCZ0GA3 MK-1775 Malignant melanoma (Cell Line: RPMI7951) [3]
MK-1775 + MK-4827 DCXL4GW MK-1775 Malignant melanoma (Cell Line: SKMEL30) [3]
MK-1775 + MK-4827 DCSSQGR MK-1775 Non small cell carcinoma (Cell Line: SKMES1) [3]
MK-1775 + MK-4827 DCEX7IO MK-1775 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [3]
MK-1775 + MK-4827 DC8UK48 MK-1775 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
MK-1775 + MK-4827 DC94MO2 MK-1775 Prostate carcinoma (Cell Line: LNCAP) [3]
MK-1775 + MK-4827 DCP6R64 MK-1775 Prostate carcinoma (Cell Line: VCAP) [3]
MK-1775 + MK-4827 DCMMN8B MK-1775 Breast carcinoma (Cell Line: ZR751) [4]
MK-1775 + MK-4827 DCPCLUJ MK-1775 Breast carcinoma (Cell Line: KPL1) [4]
MK-1775 + MK-4827 DCBUPX3 MK-1775 Breast carcinoma (Cell Line: OCUBM) [4]
MK-1775 + MK-4827 DC0IWEK MK-1775 Carcinoma (Cell Line: EFM192B) [4]
MK-1775 + MK-4827 DC6J8HT MK-1775 Colon adenocarcinoma (Cell Line: LOVO) [4]
MK-1775 + MK-4827 DC39R1W MK-1775 Colon carcinoma (Cell Line: RKO) [4]
MK-1775 + MK-4827 DCB4CSV MK-1775 Invasive ductal carcinoma (Cell Line: T-47D) [4]
MK-1775 + MK-4827 DC03UAA MK-1775 Rectal adenocarcinoma (Cell Line: SW837) [4]
MK-2206 + MK-4827 DCSSUSV MK-2206 Adenocarcinoma (Cell Line: CAOV3) [3]
MK-2206 + MK-4827 DC6NTIW MK-2206 Adenocarcinoma (Cell Line: OVCAR3) [3]
MK-2206 + MK-4827 DCUOUSC MK-2206 Adenocarcinoma (Cell Line: A427) [3]
MK-2206 + MK-4827 DCTX7DZ MK-2206 Adenocarcinoma (Cell Line: NCIH1650) [3]
MK-2206 + MK-4827 DCXZNOK MK-2206 Adenocarcinoma (Cell Line: NCIH2122) [3]
MK-2206 + MK-4827 DCRZWRC MK-2206 Adenocarcinoma (Cell Line: NCIH23) [3]
MK-2206 + MK-4827 DCFLUKF MK-2206 Adenocarcinoma (Cell Line: NCIH520) [3]
MK-2206 + MK-4827 DCQ5930 MK-2206 Adenocarcinoma (Cell Line: COLO320DM) [3]
MK-2206 + MK-4827 DC56Y63 MK-2206 Adenocarcinoma (Cell Line: DLD1) [3]
MK-2206 + MK-4827 DCLRUJV MK-2206 Adenocarcinoma (Cell Line: HCT116) [3]
MK-2206 + MK-4827 DC4V7D6 MK-2206 Adenocarcinoma (Cell Line: HT29) [3]
MK-2206 + MK-4827 DC6PSOL MK-2206 Adenocarcinoma (Cell Line: SW-620) [3]
MK-2206 + MK-4827 DCLKM9B MK-2206 Amelanotic melanoma (Cell Line: A2058) [3]
MK-2206 + MK-4827 DCLU5O8 MK-2206 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
MK-2206 + MK-4827 DC0E0CB MK-2206 Germ cell tumour (Cell Line: PA1) [3]
MK-2206 + MK-4827 DCMJ6NE MK-2206 Large cell lung carcinoma (Cell Line: NCI-H460) [3]
MK-2206 + MK-4827 DCVFCWU MK-2206 Malignant melanoma (Cell Line: A375) [3]
MK-2206 + MK-4827 DC9IDR0 MK-2206 Malignant melanoma (Cell Line: HT144) [3]
MK-2206 + MK-4827 DCB7NCC MK-2206 Malignant melanoma (Cell Line: RPMI7951) [3]
MK-2206 + MK-4827 DCSPTQ5 MK-2206 Malignant melanoma (Cell Line: SKMEL30) [3]
MK-2206 + MK-4827 DC9FVKQ MK-2206 Malignant melanoma (Cell Line: UACC62) [3]
MK-2206 + MK-4827 DCGZD4Z MK-2206 Mesothelioma (Cell Line: MSTO) [3]
MK-2206 + MK-4827 DCJBWKJ MK-2206 Non small cell carcinoma (Cell Line: SKMES1) [3]
MK-2206 + MK-4827 DC26H0N MK-2206 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [3]
MK-2206 + MK-4827 DC41BAX MK-2206 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
MK-2206 + MK-4827 DC2RD92 MK-2206 Prostate carcinoma (Cell Line: LNCAP) [3]
MK-2206 + MK-4827 DCN3MHL MK-2206 Prostate carcinoma (Cell Line: VCAP) [3]
MK-2206 + MK-4827 DCFG80X MK-2206 Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
MK-2206 + MK-4827 DCPS202 MK-2206 Breast carcinoma (Cell Line: KPL1) [4]
MK-2206 + MK-4827 DCADZ15 MK-2206 Breast carcinoma (Cell Line: OCUBM) [4]
MK-2206 + MK-4827 DCY2WT1 MK-2206 Carcinoma (Cell Line: OV90) [4]
MK-2206 + MK-4827 DCEQC76 MK-2206 Carcinoma (Cell Line: EFM192B) [4]
MK-2206 + MK-4827 DCGHF2G MK-2206 Carcinoma (Cell Line: MDAMB436) [4]
MK-2206 + MK-4827 DCA6YBG MK-2206 Colon adenocarcinoma (Cell Line: LOVO) [4]
MK-2206 + MK-4827 DCFLCNU MK-2206 Colon carcinoma (Cell Line: RKO) [4]
MK-2206 + MK-4827 DCBWQD3 MK-2206 Invasive ductal carcinoma (Cell Line: T-47D) [4]
MK-4827 + RTB101 DCD723T RTB101 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
MK-4827 + SCH-900776 DC386N8 SCH-900776 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
MK-4827 + SNX-2112 DCQOSV7 SNX-2112 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
MK-4827 + Marizomib DC8BGNB Marizomib Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [3]
MK-4827 + Ridaforolimus DCFE32M Ridaforolimus Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
MK-4827 + Idarubicin DC2D9RP Idarubicin Glioblastoma? (Cell Line: T98G) [3]
MK-4827 + Sorafenib DCNCD2R Sorafenib Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
MK-4827 + Vorinostat DCS4G54 Vorinostat Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
MK-4827 + RTB101 DCU6HS1 RTB101 Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
MK-4827 + RTB101 DC84CA9 RTB101 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
MK-4827 + RTB101 DCN7SGM RTB101 Breast carcinoma (Cell Line: ZR751) [4]
MK-4827 + RTB101 DC87O78 RTB101 Breast carcinoma (Cell Line: KPL1) [4]
MK-4827 + RTB101 DCKIE1M RTB101 Breast carcinoma (Cell Line: OCUBM) [4]
MK-4827 + RTB101 DCEELWL RTB101 Carcinoma (Cell Line: OV90) [4]
MK-4827 + RTB101 DCZIJID RTB101 Carcinoma (Cell Line: EFM192B) [4]
MK-4827 + RTB101 DC2MZW9 RTB101 Carcinoma (Cell Line: MDAMB436) [4]
MK-4827 + RTB101 DCK01CR RTB101 Colon adenocarcinoma (Cell Line: LOVO) [4]
MK-4827 + RTB101 DCP62QP RTB101 Colon carcinoma (Cell Line: RKO) [4]
MK-4827 + RTB101 DCM5A9G RTB101 Invasive ductal carcinoma (Cell Line: T-47D) [4]
MK-4827 + RTB101 DC0MC7G RTB101 Rectal adenocarcinoma (Cell Line: SW837) [4]
MK-4827 + SCH-900776 DCUNSD2 SCH-900776 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
MK-4827 + SCH-900776 DC8BAL5 SCH-900776 Breast carcinoma (Cell Line: KPL1) [4]
MK-4827 + SCH-900776 DC54IHN SCH-900776 Breast carcinoma (Cell Line: OCUBM) [4]
MK-4827 + SCH-900776 DCU2Y1O SCH-900776 Carcinoma (Cell Line: OV90) [4]
MK-4827 + SCH-900776 DCDZ94E SCH-900776 Carcinoma (Cell Line: MDAMB436) [4]
MK-4827 + SCH-900776 DCU5P5B SCH-900776 Colon carcinoma (Cell Line: RKO) [4]
MK-4827 + SCH-900776 DCQGSFQ SCH-900776 Rectal adenocarcinoma (Cell Line: SW837) [4]
MK-4827 + 10-hydroxycamptothecin DC3QOO0 10-hydroxycamptothecin Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
MK-4827 + 10-hydroxycamptothecin DCSAYP9 10-hydroxycamptothecin Breast carcinoma (Cell Line: KPL1) [4]
MK-4827 + 10-hydroxycamptothecin DCL7X4H 10-hydroxycamptothecin Breast carcinoma (Cell Line: OCUBM) [4]
MK-4827 + 10-hydroxycamptothecin DCSYC51 10-hydroxycamptothecin Carcinoma (Cell Line: EFM192B) [4]
MK-4827 + SNX-2112 DC863YI SNX-2112 Breast carcinoma (Cell Line: ZR751) [4]
MK-4827 + SNX-2112 DC7HYCK SNX-2112 Breast carcinoma (Cell Line: KPL1) [4]
MK-4827 + SNX-2112 DCA9DX4 SNX-2112 Breast carcinoma (Cell Line: OCUBM) [4]
MK-4827 + SNX-2112 DCJ44T6 SNX-2112 Carcinoma (Cell Line: OV90) [4]
MK-4827 + SNX-2112 DC6Z2I9 SNX-2112 Carcinoma (Cell Line: EFM192B) [4]
MK-4827 + SNX-2112 DCYZGOT SNX-2112 Carcinoma (Cell Line: MDAMB436) [4]
MK-4827 + SNX-2112 DC2ROHE SNX-2112 Colon adenocarcinoma (Cell Line: LOVO) [4]
MK-4827 + SNX-2112 DCQIQ79 SNX-2112 Colon carcinoma (Cell Line: RKO) [4]
MK-4827 + SNX-2112 DC0XGVK SNX-2112 Invasive ductal carcinoma (Cell Line: T-47D) [4]
MK-4827 + SNX-2112 DCN643W SNX-2112 Rectal adenocarcinoma (Cell Line: SW837) [4]
MK-4827 + Ridaforolimus DCZDKU8 Ridaforolimus Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
MK-4827 + Ridaforolimus DCPRVAD Ridaforolimus Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
MK-4827 + Ridaforolimus DCDUHPX Ridaforolimus Breast carcinoma (Cell Line: ZR751) [4]
MK-4827 + Ridaforolimus DCWNYY8 Ridaforolimus Breast carcinoma (Cell Line: KPL1) [4]
MK-4827 + Ridaforolimus DCD43IB Ridaforolimus Breast carcinoma (Cell Line: OCUBM) [4]
MK-4827 + Ridaforolimus DCCLN9V Ridaforolimus Carcinoma (Cell Line: OV90) [4]
MK-4827 + Ridaforolimus DCCLJF5 Ridaforolimus Carcinoma (Cell Line: EFM192B) [4]
MK-4827 + Ridaforolimus DCGQXQR Ridaforolimus Carcinoma (Cell Line: MDAMB436) [4]
MK-4827 + Ridaforolimus DC4ZUBL Ridaforolimus Colon carcinoma (Cell Line: RKO) [4]
MK-4827 + Ridaforolimus DC42T8R Ridaforolimus Invasive ductal carcinoma (Cell Line: T-47D) [4]
MK-4827 + Ridaforolimus DCBPG0V Ridaforolimus Rectal adenocarcinoma (Cell Line: SW837) [4]
MK-4827 + Lomustine DCIAR1N Lomustine Breast carcinoma (Cell Line: KPL1) [4]
MK-4827 + Lomustine DCJLCYS Lomustine Breast carcinoma (Cell Line: OCUBM) [4]
MK-4827 + Sorafenib DCYM93L Sorafenib Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
MK-4827 + Sorafenib DCPTORE Sorafenib Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
MK-4827 + Sorafenib DCV7SVS Sorafenib Breast carcinoma (Cell Line: ZR751) [4]
MK-4827 + Sorafenib DCQZ56N Sorafenib Breast carcinoma (Cell Line: KPL1) [4]
MK-4827 + Sorafenib DC9E34I Sorafenib Breast carcinoma (Cell Line: OCUBM) [4]
MK-4827 + Sorafenib DC9P8WI Sorafenib Carcinoma (Cell Line: OV90) [4]
MK-4827 + Sorafenib DCTXXJY Sorafenib Carcinoma (Cell Line: EFM192B) [4]
MK-4827 + Sorafenib DCHLX3E Sorafenib Carcinoma (Cell Line: MDAMB436) [4]
MK-4827 + Sorafenib DCULKBQ Sorafenib Colon adenocarcinoma (Cell Line: LOVO) [4]
MK-4827 + Sorafenib DCF8BJ9 Sorafenib Colon carcinoma (Cell Line: RKO) [4]
MK-4827 + Sorafenib DC0BHMF Sorafenib Invasive ductal carcinoma (Cell Line: T-47D) [4]
MK-4827 + Sorafenib DC6CQGY Sorafenib Rectal adenocarcinoma (Cell Line: SW837) [4]
MK-4827 + Vorinostat DC4CE3X Vorinostat Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
MK-4827 + Vorinostat DC46UW6 Vorinostat Breast carcinoma (Cell Line: KPL1) [4]
MK-4827 + Vorinostat DCGZ38Z Vorinostat Carcinoma (Cell Line: EFM192B) [4]
MK-4827 + Vorinostat DC9V27I Vorinostat Colon adenocarcinoma (Cell Line: LOVO) [4]
MK-4827 + Vorinostat DC8SFSF Vorinostat Colon carcinoma (Cell Line: RKO) [4]
MK-4827 + Vorinostat DCDU05D Vorinostat Invasive ductal carcinoma (Cell Line: T-47D) [4]
MK-4827 + RTB101 DC73NTU RTB101 Adenocarcinoma (Cell Line: CAOV3) [5]
MK-4827 + RTB101 DCRA69Y RTB101 Adenocarcinoma (Cell Line: OVCAR3) [5]
MK-4827 + RTB101 DC41PDY RTB101 Adenocarcinoma (Cell Line: A427) [5]
MK-4827 + RTB101 DCDD7TA RTB101 Adenocarcinoma (Cell Line: NCIH1650) [5]
MK-4827 + RTB101 DCXJT2O RTB101 Adenocarcinoma (Cell Line: NCIH2122) [5]
MK-4827 + RTB101 DCVSPSC RTB101 Adenocarcinoma (Cell Line: NCIH23) [5]
MK-4827 + RTB101 DCFMSGR RTB101 Adenocarcinoma (Cell Line: NCIH520) [5]
MK-4827 + RTB101 DCLO61D RTB101 Adenocarcinoma (Cell Line: COLO320DM) [5]
MK-4827 + RTB101 DCP3DTI RTB101 Adenocarcinoma (Cell Line: DLD1) [5]
MK-4827 + RTB101 DCGIHIB RTB101 Adenocarcinoma (Cell Line: HCT116) [5]
MK-4827 + RTB101 DC2I1PQ RTB101 Adenocarcinoma (Cell Line: HT29) [5]
MK-4827 + RTB101 DC0SQ46 RTB101 Adenocarcinoma (Cell Line: SW-620) [5]
MK-4827 + RTB101 DCMIY7Q RTB101 Amelanotic melanoma (Cell Line: A2058) [5]
MK-4827 + RTB101 DCE28IL RTB101 Germ cell tumour (Cell Line: PA1) [5]
MK-4827 + RTB101 DCC4HKB RTB101 Large cell lung carcinoma (Cell Line: NCI-H460) [5]
MK-4827 + RTB101 DC1SLZC RTB101 Malignant melanoma (Cell Line: HT144) [5]
MK-4827 + RTB101 DC5ENSD RTB101 Malignant melanoma (Cell Line: RPMI7951) [5]
MK-4827 + RTB101 DCVFPMO RTB101 Malignant melanoma (Cell Line: SKMEL30) [5]
MK-4827 + RTB101 DCBT7KV RTB101 Malignant melanoma (Cell Line: UACC62) [5]
MK-4827 + RTB101 DCDIM50 RTB101 Malignant melanoma (Cell Line: A375) [5]
MK-4827 + RTB101 DCGNDWF RTB101 Mesothelioma (Cell Line: MSTO) [5]
MK-4827 + RTB101 DCTEKI5 RTB101 Non small cell carcinoma (Cell Line: SKMES1) [5]
MK-4827 + RTB101 DCICY6D RTB101 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
MK-4827 + RTB101 DCBA8UJ RTB101 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
MK-4827 + RTB101 DCMZVH6 RTB101 Prostate carcinoma (Cell Line: LNCAP) [5]
MK-4827 + RTB101 DCCKFAM RTB101 Prostate carcinoma (Cell Line: VCAP) [5]
MK-4827 + SCH-900776 DCJCNIO SCH-900776 Adenocarcinoma (Cell Line: CAOV3) [5]
MK-4827 + SCH-900776 DC2ECJ4 SCH-900776 Adenocarcinoma (Cell Line: OVCAR3) [5]
MK-4827 + SCH-900776 DCTHA6M SCH-900776 Adenocarcinoma (Cell Line: A427) [5]
MK-4827 + SCH-900776 DC4K3HZ SCH-900776 Adenocarcinoma (Cell Line: NCIH2122) [5]
MK-4827 + SCH-900776 DCIFKNW SCH-900776 Adenocarcinoma (Cell Line: NCIH23) [5]
MK-4827 + SCH-900776 DCLTPD7 SCH-900776 Adenocarcinoma (Cell Line: COLO320DM) [5]
MK-4827 + SCH-900776 DC8OA8H SCH-900776 Adenocarcinoma (Cell Line: DLD1) [5]
MK-4827 + SCH-900776 DCCTRVY SCH-900776 Adenocarcinoma (Cell Line: HT29) [5]
MK-4827 + SCH-900776 DCYKMNN SCH-900776 Amelanotic melanoma (Cell Line: A2058) [5]
MK-4827 + SCH-900776 DC1TZ3T SCH-900776 Germ cell tumour (Cell Line: PA1) [5]
MK-4827 + SCH-900776 DCB1LP2 SCH-900776 Large cell lung carcinoma (Cell Line: NCI-H460) [5]
MK-4827 + SCH-900776 DC1DY7H SCH-900776 Malignant melanoma (Cell Line: A375) [5]
MK-4827 + SCH-900776 DC6MF7R SCH-900776 Malignant melanoma (Cell Line: HT144) [5]
MK-4827 + SCH-900776 DCL5VYC SCH-900776 Malignant melanoma (Cell Line: RPMI7951) [5]
MK-4827 + SCH-900776 DCC65TQ SCH-900776 Malignant melanoma (Cell Line: SKMEL30) [5]
MK-4827 + SCH-900776 DCPFW2S SCH-900776 Malignant melanoma (Cell Line: UACC62) [5]
MK-4827 + SCH-900776 DC5NJSB SCH-900776 Mesothelioma (Cell Line: MSTO) [5]
MK-4827 + SCH-900776 DCFLMGE SCH-900776 Non small cell carcinoma (Cell Line: SKMES1) [5]
MK-4827 + SCH-900776 DC23HDQ SCH-900776 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
MK-4827 + SCH-900776 DCPYSTM SCH-900776 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
MK-4827 + 10-hydroxycamptothecin DCQEWFZ 10-hydroxycamptothecin Adenocarcinoma (Cell Line: CAOV3) [5]
MK-4827 + 10-hydroxycamptothecin DCZ9C5V 10-hydroxycamptothecin Adenocarcinoma (Cell Line: OVCAR3) [5]
MK-4827 + 10-hydroxycamptothecin DCGTHLV 10-hydroxycamptothecin Adenocarcinoma (Cell Line: A427) [5]
MK-4827 + 10-hydroxycamptothecin DCDYXZW 10-hydroxycamptothecin Adenocarcinoma (Cell Line: NCIH2122) [5]
MK-4827 + 10-hydroxycamptothecin DCFT0CP 10-hydroxycamptothecin Adenocarcinoma (Cell Line: HT29) [5]
MK-4827 + 10-hydroxycamptothecin DCDVMON 10-hydroxycamptothecin Amelanotic melanoma (Cell Line: A2058) [5]
MK-4827 + 10-hydroxycamptothecin DCN7Q9T 10-hydroxycamptothecin Germ cell tumour (Cell Line: PA1) [5]
MK-4827 + 10-hydroxycamptothecin DCLCK79 10-hydroxycamptothecin Malignant melanoma (Cell Line: HT144) [5]
MK-4827 + 10-hydroxycamptothecin DCYXQT0 10-hydroxycamptothecin Malignant melanoma (Cell Line: UACC62) [5]
MK-4827 + 10-hydroxycamptothecin DCY0W6B 10-hydroxycamptothecin Malignant melanoma (Cell Line: RPMI7951) [5]
MK-4827 + 10-hydroxycamptothecin DCB8GMJ 10-hydroxycamptothecin Mesothelioma (Cell Line: MSTO) [5]
MK-4827 + 10-hydroxycamptothecin DC36PMW 10-hydroxycamptothecin Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
MK-4827 + 10-hydroxycamptothecin DCMT4I4 10-hydroxycamptothecin Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
MK-4827 + 10-hydroxycamptothecin DC979RX 10-hydroxycamptothecin Prostate carcinoma (Cell Line: VCAP) [5]
MK-4827 + SNX-2112 DCIKDDC SNX-2112 Adenocarcinoma (Cell Line: CAOV3) [5]
MK-4827 + SNX-2112 DC0L2WK SNX-2112 Adenocarcinoma (Cell Line: OVCAR3) [5]
MK-4827 + SNX-2112 DCHW25O SNX-2112 Adenocarcinoma (Cell Line: A427) [5]
MK-4827 + SNX-2112 DCZZOHN SNX-2112 Adenocarcinoma (Cell Line: NCIH1650) [5]
MK-4827 + SNX-2112 DCVNSN7 SNX-2112 Adenocarcinoma (Cell Line: NCIH2122) [5]
MK-4827 + SNX-2112 DCNL3AP SNX-2112 Adenocarcinoma (Cell Line: NCIH23) [5]
MK-4827 + SNX-2112 DCFNTKC SNX-2112 Adenocarcinoma (Cell Line: NCIH520) [5]
MK-4827 + SNX-2112 DCYAYYW SNX-2112 Adenocarcinoma (Cell Line: COLO320DM) [5]
MK-4827 + SNX-2112 DCVFKNW SNX-2112 Adenocarcinoma (Cell Line: DLD1) [5]
MK-4827 + SNX-2112 DCI0IQB SNX-2112 Adenocarcinoma (Cell Line: HCT116) [5]
MK-4827 + SNX-2112 DC8VEIK SNX-2112 Adenocarcinoma (Cell Line: HT29) [5]
MK-4827 + SNX-2112 DCEKHIK SNX-2112 Adenocarcinoma (Cell Line: SW-620) [5]
MK-4827 + SNX-2112 DC8ESVA SNX-2112 Amelanotic melanoma (Cell Line: A2058) [5]
MK-4827 + SNX-2112 DCJT3AG SNX-2112 Germ cell tumour (Cell Line: PA1) [5]
MK-4827 + SNX-2112 DCFXI48 SNX-2112 Large cell lung carcinoma (Cell Line: NCI-H460) [5]
MK-4827 + SNX-2112 DCBPB7L SNX-2112 Malignant melanoma (Cell Line: HT144) [5]
MK-4827 + SNX-2112 DCCYUYS SNX-2112 Malignant melanoma (Cell Line: SKMEL30) [5]
MK-4827 + SNX-2112 DC96WY2 SNX-2112 Malignant melanoma (Cell Line: UACC62) [5]
MK-4827 + SNX-2112 DC8Q5PN SNX-2112 Malignant melanoma (Cell Line: A375) [5]
MK-4827 + SNX-2112 DCX2XY6 SNX-2112 Mesothelioma (Cell Line: MSTO) [5]
MK-4827 + SNX-2112 DCJL92N SNX-2112 Non small cell carcinoma (Cell Line: SKMES1) [5]
MK-4827 + SNX-2112 DCHMI4S SNX-2112 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
MK-4827 + SNX-2112 DCPDGB7 SNX-2112 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
MK-4827 + SNX-2112 DCPGJ6F SNX-2112 Prostate carcinoma (Cell Line: LNCAP) [5]
MK-4827 + SNX-2112 DCWDV0K SNX-2112 Prostate carcinoma (Cell Line: VCAP) [5]
MK-4827 + Ridaforolimus DC64MA2 Ridaforolimus Adenocarcinoma (Cell Line: CAOV3) [5]
MK-4827 + Ridaforolimus DCNPSKT Ridaforolimus Adenocarcinoma (Cell Line: OVCAR3) [5]
MK-4827 + Ridaforolimus DCFVPZL Ridaforolimus Adenocarcinoma (Cell Line: NCIH1650) [5]
MK-4827 + Ridaforolimus DCI85EV Ridaforolimus Adenocarcinoma (Cell Line: NCIH2122) [5]
MK-4827 + Ridaforolimus DCTKCSW Ridaforolimus Adenocarcinoma (Cell Line: NCIH23) [5]
MK-4827 + Ridaforolimus DCW6IX0 Ridaforolimus Adenocarcinoma (Cell Line: COLO320DM) [5]
MK-4827 + Ridaforolimus DCZX6WL Ridaforolimus Adenocarcinoma (Cell Line: DLD1) [5]
MK-4827 + Ridaforolimus DCKF7RE Ridaforolimus Amelanotic melanoma (Cell Line: A2058) [5]
MK-4827 + Ridaforolimus DCFFX4H Ridaforolimus Germ cell tumour (Cell Line: PA1) [5]
MK-4827 + Ridaforolimus DC05ILJ Ridaforolimus Large cell lung carcinoma (Cell Line: NCI-H460) [5]
MK-4827 + Ridaforolimus DCYI9EL Ridaforolimus Malignant melanoma (Cell Line: A375) [5]
MK-4827 + Ridaforolimus DCHL0Z9 Ridaforolimus Malignant melanoma (Cell Line: RPMI7951) [5]
MK-4827 + Ridaforolimus DCSZLAH Ridaforolimus Malignant melanoma (Cell Line: SKMEL30) [5]
MK-4827 + Ridaforolimus DCZ89NM Ridaforolimus Malignant melanoma (Cell Line: UACC62) [5]
MK-4827 + Ridaforolimus DCLTYOX Ridaforolimus Mesothelioma (Cell Line: MSTO) [5]
MK-4827 + Ridaforolimus DC02439 Ridaforolimus Non small cell carcinoma (Cell Line: SKMES1) [5]
MK-4827 + Ridaforolimus DCXZMTP Ridaforolimus Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
MK-4827 + Ridaforolimus DCXQHDR Ridaforolimus Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
MK-4827 + Ridaforolimus DCRW6IB Ridaforolimus Prostate carcinoma (Cell Line: LNCAP) [5]
MK-4827 + Lomustine DCO4EYL Lomustine Adenocarcinoma (Cell Line: A427) [5]
MK-4827 + Lomustine DCQ2W8I Lomustine Adenocarcinoma (Cell Line: COLO320DM) [5]
MK-4827 + Lomustine DCTX38O Lomustine Adenocarcinoma (Cell Line: HCT116) [5]
MK-4827 + Lomustine DC4N6KT Lomustine Amelanotic melanoma (Cell Line: A2058) [5]
MK-4827 + Lomustine DCFHQT6 Lomustine Malignant melanoma (Cell Line: SKMEL30) [5]
MK-4827 + Lomustine DCI5OIV Lomustine Mesothelioma (Cell Line: MSTO) [5]
MK-4827 + Lomustine DCPHRAI Lomustine Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
MK-4827 + Lomustine DCLAI9Q Lomustine Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
MK-4827 + Lomustine DCMN5NA Lomustine Prostate carcinoma (Cell Line: LNCAP) [5]
MK-4827 + Lomustine DCQYX7M Lomustine Prostate carcinoma (Cell Line: VCAP) [5]
MK-4827 + Sorafenib DCKEKRZ Sorafenib Adenocarcinoma (Cell Line: CAOV3) [5]
MK-4827 + Sorafenib DCYJPAY Sorafenib Adenocarcinoma (Cell Line: OVCAR3) [5]
MK-4827 + Sorafenib DCHVOJ1 Sorafenib Adenocarcinoma (Cell Line: A427) [5]
MK-4827 + Sorafenib DCIJ729 Sorafenib Adenocarcinoma (Cell Line: NCIH1650) [5]
MK-4827 + Sorafenib DC7IGOZ Sorafenib Adenocarcinoma (Cell Line: NCIH2122) [5]
MK-4827 + Sorafenib DCOT7Z5 Sorafenib Adenocarcinoma (Cell Line: NCIH23) [5]
MK-4827 + Sorafenib DCKHXU2 Sorafenib Adenocarcinoma (Cell Line: NCIH520) [5]
MK-4827 + Sorafenib DC9T68E Sorafenib Adenocarcinoma (Cell Line: COLO320DM) [5]
MK-4827 + Sorafenib DCJXZK1 Sorafenib Adenocarcinoma (Cell Line: DLD1) [5]
MK-4827 + Sorafenib DC6N11M Sorafenib Adenocarcinoma (Cell Line: HCT116) [5]
MK-4827 + Sorafenib DC3TKGF Sorafenib Adenocarcinoma (Cell Line: HT29) [5]
MK-4827 + Sorafenib DC3MNO2 Sorafenib Adenocarcinoma (Cell Line: SW-620) [5]
MK-4827 + Sorafenib DCAK7EM Sorafenib Amelanotic melanoma (Cell Line: A2058) [5]
MK-4827 + Sorafenib DCBVNRF Sorafenib Large cell lung carcinoma (Cell Line: NCI-H460) [5]
MK-4827 + Sorafenib DC7U5LQ Sorafenib Malignant melanoma (Cell Line: A375) [5]
MK-4827 + Sorafenib DCMUFUL Sorafenib Malignant melanoma (Cell Line: HT144) [5]
MK-4827 + Sorafenib DCE5Z8I Sorafenib Malignant melanoma (Cell Line: SKMEL30) [5]
MK-4827 + Sorafenib DCST48U Sorafenib Malignant melanoma (Cell Line: UACC62) [5]
MK-4827 + Sorafenib DCHAPDI Sorafenib Mesothelioma (Cell Line: MSTO) [5]
MK-4827 + Sorafenib DCMHL0J Sorafenib Non small cell carcinoma (Cell Line: SKMES1) [5]
MK-4827 + Sorafenib DCO3GCK Sorafenib Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
MK-4827 + Sorafenib DCT8R7N Sorafenib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
MK-4827 + Sorafenib DC5HA32 Sorafenib Prostate carcinoma (Cell Line: LNCAP) [5]
MK-4827 + Sorafenib DCR1ZQO Sorafenib Prostate carcinoma (Cell Line: VCAP) [5]
MK-4827 + Vorinostat DC2KGL8 Vorinostat Adenocarcinoma (Cell Line: CAOV3) [5]
MK-4827 + Vorinostat DC2KWCJ Vorinostat Adenocarcinoma (Cell Line: OVCAR3) [5]
MK-4827 + Vorinostat DCXW6ZW Vorinostat Adenocarcinoma (Cell Line: A427) [5]
MK-4827 + Vorinostat DCAWLWZ Vorinostat Adenocarcinoma (Cell Line: NCIH1650) [5]
MK-4827 + Vorinostat DCC5MW7 Vorinostat Adenocarcinoma (Cell Line: NCIH2122) [5]
MK-4827 + Vorinostat DCLDAS5 Vorinostat Adenocarcinoma (Cell Line: NCIH520) [5]
MK-4827 + Vorinostat DC82E4Q Vorinostat Adenocarcinoma (Cell Line: COLO320DM) [5]
MK-4827 + Vorinostat DC9WLZR Vorinostat Adenocarcinoma (Cell Line: DLD1) [5]
MK-4827 + Vorinostat DC973KC Vorinostat Adenocarcinoma (Cell Line: HCT116) [5]
MK-4827 + Vorinostat DCMP2NX Vorinostat Adenocarcinoma (Cell Line: HT29) [5]
MK-4827 + Vorinostat DCWOABF Vorinostat Adenocarcinoma (Cell Line: SW-620) [5]
MK-4827 + Vorinostat DCCVM9I Vorinostat Large cell lung carcinoma (Cell Line: NCI-H460) [5]
MK-4827 + Vorinostat DCWBS26 Vorinostat Malignant melanoma (Cell Line: A375) [5]
MK-4827 + Vorinostat DCBTCDD Vorinostat Malignant melanoma (Cell Line: HT144) [5]
MK-4827 + Vorinostat DCGG9NF Vorinostat Malignant melanoma (Cell Line: RPMI7951) [5]
MK-4827 + Vorinostat DC2JYBE Vorinostat Malignant melanoma (Cell Line: SKMEL30) [5]
MK-4827 + Vorinostat DCO84UU Vorinostat Malignant melanoma (Cell Line: UACC62) [5]
MK-4827 + Vorinostat DC3HB5O Vorinostat Mesothelioma (Cell Line: MSTO) [5]
MK-4827 + Vorinostat DCY5P9Z Vorinostat Non small cell carcinoma (Cell Line: SKMES1) [5]
MK-4827 + Vorinostat DC80YXF Vorinostat Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
MK-4827 + Vorinostat DC6V2DG Vorinostat Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
MK-4827 + Vorinostat DC7JVX4 Vorinostat Prostate carcinoma (Cell Line: VCAP) [5]
MK-5108 + MK-4827 DCBGGSO MK-5108 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
MK-5108 + MK-4827 DC22EC6 MK-5108 Breast carcinoma (Cell Line: KPL1) [4]
MK-5108 + MK-4827 DCOJGWP MK-5108 Breast carcinoma (Cell Line: OCUBM) [4]
MK-5108 + MK-4827 DCSQ5YL MK-5108 Carcinoma (Cell Line: EFM192B) [4]
MK-5108 + MK-4827 DCLKJ8Q MK-5108 Colon carcinoma (Cell Line: RKO) [4]
MK-5108 + MK-4827 DCDIC8Q MK-5108 Invasive ductal carcinoma (Cell Line: T-47D) [4]
MK-5108 + MK-4827 DC30C6P MK-5108 Rectal adenocarcinoma (Cell Line: SW837) [4]
MK-5108 + MK-4827 DC5W0QB MK-5108 Adenocarcinoma (Cell Line: CAOV3) [5]
MK-5108 + MK-4827 DCPONMC MK-5108 Adenocarcinoma (Cell Line: OVCAR3) [5]
MK-5108 + MK-4827 DCR8G24 MK-5108 Adenocarcinoma (Cell Line: A427) [5]
MK-5108 + MK-4827 DCO2W8T MK-5108 Adenocarcinoma (Cell Line: NCIH2122) [5]
MK-5108 + MK-4827 DCNYE0W MK-5108 Adenocarcinoma (Cell Line: NCIH520) [5]
MK-5108 + MK-4827 DCOTPP6 MK-5108 Adenocarcinoma (Cell Line: COLO320DM) [5]
MK-5108 + MK-4827 DCGZ7WH MK-5108 Adenocarcinoma (Cell Line: DLD1) [5]
MK-5108 + MK-4827 DCE21DR MK-5108 Adenocarcinoma (Cell Line: HCT116) [5]
MK-5108 + MK-4827 DCT21UE MK-5108 Adenocarcinoma (Cell Line: HT29) [5]
MK-5108 + MK-4827 DCC3F5K MK-5108 Adenocarcinoma (Cell Line: SW-620) [5]
MK-5108 + MK-4827 DC0XA7R MK-5108 Amelanotic melanoma (Cell Line: A2058) [5]
MK-5108 + MK-4827 DCQO4VA MK-5108 Malignant melanoma (Cell Line: A375) [5]
MK-5108 + MK-4827 DC2QYN9 MK-5108 Malignant melanoma (Cell Line: RPMI7951) [5]
MK-5108 + MK-4827 DCND5UR MK-5108 Malignant melanoma (Cell Line: SKMEL30) [5]
MK-5108 + MK-4827 DCXDZ90 MK-5108 Mesothelioma (Cell Line: MSTO) [5]
MK-5108 + MK-4827 DCTRTM1 MK-5108 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
MK-5108 + MK-4827 DCKW65Q MK-5108 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
MK-5108 + MK-4827 DCFEYQ1 MK-5108 Prostate carcinoma (Cell Line: VCAP) [5]
PD-0325901 + MK-4827 DC6ALAV PD-0325901 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
PD-0325901 + MK-4827 DC7RHBL PD-0325901 Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
PD-0325901 + MK-4827 DCT1DD8 PD-0325901 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
PD-0325901 + MK-4827 DCHE11I PD-0325901 Breast carcinoma (Cell Line: KPL1) [4]
PD-0325901 + MK-4827 DCZB8XI PD-0325901 Breast carcinoma (Cell Line: OCUBM) [4]
PD-0325901 + MK-4827 DCDYPBP PD-0325901 Carcinoma (Cell Line: OV90) [4]
PD-0325901 + MK-4827 DCFMCTM PD-0325901 Carcinoma (Cell Line: EFM192B) [4]
PD-0325901 + MK-4827 DCSZ68H PD-0325901 Carcinoma (Cell Line: MDAMB436) [4]
PD-0325901 + MK-4827 DC3BO78 PD-0325901 Colon adenocarcinoma (Cell Line: LOVO) [4]
PD-0325901 + MK-4827 DCU8IG6 PD-0325901 Colon carcinoma (Cell Line: RKO) [4]
PD-0325901 + MK-4827 DCHAHNU PD-0325901 Invasive ductal carcinoma (Cell Line: T-47D) [4]
PD-0325901 + MK-4827 DC2IQNQ PD-0325901 Rectal adenocarcinoma (Cell Line: SW837) [4]
PD-0325901 + MK-4827 DCBMWSA PD-0325901 Adenocarcinoma (Cell Line: CAOV3) [5]
PD-0325901 + MK-4827 DCUN9PE PD-0325901 Adenocarcinoma (Cell Line: OVCAR3) [5]
PD-0325901 + MK-4827 DCKQZEF PD-0325901 Adenocarcinoma (Cell Line: A427) [5]
PD-0325901 + MK-4827 DCNS8GB PD-0325901 Adenocarcinoma (Cell Line: NCIH1650) [5]
PD-0325901 + MK-4827 DC9XLJI PD-0325901 Adenocarcinoma (Cell Line: NCIH2122) [5]
PD-0325901 + MK-4827 DCSQA1C PD-0325901 Adenocarcinoma (Cell Line: NCIH23) [5]
PD-0325901 + MK-4827 DCIVPT4 PD-0325901 Adenocarcinoma (Cell Line: NCIH520) [5]
PD-0325901 + MK-4827 DC533HJ PD-0325901 Adenocarcinoma (Cell Line: COLO320DM) [5]
PD-0325901 + MK-4827 DC1GC43 PD-0325901 Adenocarcinoma (Cell Line: DLD1) [5]
PD-0325901 + MK-4827 DC3TPSP PD-0325901 Adenocarcinoma (Cell Line: HCT116) [5]
PD-0325901 + MK-4827 DCUQR5Y PD-0325901 Adenocarcinoma (Cell Line: HT29) [5]
PD-0325901 + MK-4827 DCULF2N PD-0325901 Adenocarcinoma (Cell Line: SW-620) [5]
PD-0325901 + MK-4827 DC3JIBR PD-0325901 Amelanotic melanoma (Cell Line: A2058) [5]
PD-0325901 + MK-4827 DCF42NZ PD-0325901 Germ cell tumour (Cell Line: PA1) [5]
PD-0325901 + MK-4827 DCYS8IE PD-0325901 Large cell lung carcinoma (Cell Line: NCI-H460) [5]
PD-0325901 + MK-4827 DC8D6F1 PD-0325901 Malignant melanoma (Cell Line: A375) [5]
PD-0325901 + MK-4827 DC2QPO9 PD-0325901 Malignant melanoma (Cell Line: HT144) [5]
PD-0325901 + MK-4827 DCFV4A7 PD-0325901 Malignant melanoma (Cell Line: RPMI7951) [5]
PD-0325901 + MK-4827 DCHIK8R PD-0325901 Malignant melanoma (Cell Line: SKMEL30) [5]
PD-0325901 + MK-4827 DCIVDQA PD-0325901 Malignant melanoma (Cell Line: UACC62) [5]
PD-0325901 + MK-4827 DCC1OLM PD-0325901 Mesothelioma (Cell Line: MSTO) [5]
PD-0325901 + MK-4827 DCH1X7C PD-0325901 Non small cell carcinoma (Cell Line: SKMES1) [5]
PD-0325901 + MK-4827 DCLYF7K PD-0325901 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
PD-0325901 + MK-4827 DCBM9WB PD-0325901 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
PD-0325901 + MK-4827 DC2354G PD-0325901 Prostate carcinoma (Cell Line: VCAP) [5]
PD-0325901 + MK-4827 DC6COC0 PD-0325901 Prostate carcinoma (Cell Line: LNCAP) [5]
PMID28460551-Compound-2 + MK-4827 DCK35XT PMID28460551-Compound-2 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
PMID28460551-Compound-2 + MK-4827 DC3V4DR PMID28460551-Compound-2 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
PMID28460551-Compound-2 + MK-4827 DCBUZ7L PMID28460551-Compound-2 Breast carcinoma (Cell Line: ZR751) [4]
PMID28460551-Compound-2 + MK-4827 DC2GLOV PMID28460551-Compound-2 Breast carcinoma (Cell Line: KPL1) [4]
PMID28460551-Compound-2 + MK-4827 DCMSKSS PMID28460551-Compound-2 Breast carcinoma (Cell Line: OCUBM) [4]
PMID28460551-Compound-2 + MK-4827 DC0A5TS PMID28460551-Compound-2 Carcinoma (Cell Line: OV90) [4]
PMID28460551-Compound-2 + MK-4827 DCFZW34 PMID28460551-Compound-2 Carcinoma (Cell Line: EFM192B) [4]
PMID28460551-Compound-2 + MK-4827 DCZPHBA PMID28460551-Compound-2 Carcinoma (Cell Line: MDAMB436) [4]
PMID28460551-Compound-2 + MK-4827 DC7F46V PMID28460551-Compound-2 Colon carcinoma (Cell Line: RKO) [4]
PMID28460551-Compound-2 + MK-4827 DCP0OGN PMID28460551-Compound-2 Invasive ductal carcinoma (Cell Line: T-47D) [4]
PMID28460551-Compound-2 + MK-4827 DC3W140 PMID28460551-Compound-2 Rectal adenocarcinoma (Cell Line: SW837) [4]
PMID28460551-Compound-2 + MK-4827 DCN7ZAD PMID28460551-Compound-2 Adenocarcinoma (Cell Line: CAOV3) [5]
PMID28460551-Compound-2 + MK-4827 DCA8UOM PMID28460551-Compound-2 Adenocarcinoma (Cell Line: OVCAR3) [5]
PMID28460551-Compound-2 + MK-4827 DCFAU99 PMID28460551-Compound-2 Adenocarcinoma (Cell Line: A427) [5]
PMID28460551-Compound-2 + MK-4827 DCST9D1 PMID28460551-Compound-2 Adenocarcinoma (Cell Line: NCIH2122) [5]
PMID28460551-Compound-2 + MK-4827 DCUWRZF PMID28460551-Compound-2 Adenocarcinoma (Cell Line: NCIH23) [5]
PMID28460551-Compound-2 + MK-4827 DCKJTAU PMID28460551-Compound-2 Adenocarcinoma (Cell Line: NCIH520) [5]
PMID28460551-Compound-2 + MK-4827 DC2DMUJ PMID28460551-Compound-2 Adenocarcinoma (Cell Line: COLO320DM) [5]
PMID28460551-Compound-2 + MK-4827 DCJZOZN PMID28460551-Compound-2 Adenocarcinoma (Cell Line: DLD1) [5]
PMID28460551-Compound-2 + MK-4827 DCZLHCY PMID28460551-Compound-2 Adenocarcinoma (Cell Line: HCT116) [5]
PMID28460551-Compound-2 + MK-4827 DC062GC PMID28460551-Compound-2 Adenocarcinoma (Cell Line: HT29) [5]
PMID28460551-Compound-2 + MK-4827 DCKOWPP PMID28460551-Compound-2 Adenocarcinoma (Cell Line: SW-620) [5]
PMID28460551-Compound-2 + MK-4827 DC1DZ16 PMID28460551-Compound-2 Amelanotic melanoma (Cell Line: A2058) [5]
PMID28460551-Compound-2 + MK-4827 DC3KLLY PMID28460551-Compound-2 Germ cell tumour (Cell Line: PA1) [5]
PMID28460551-Compound-2 + MK-4827 DC42EX4 PMID28460551-Compound-2 Malignant melanoma (Cell Line: A375) [5]
PMID28460551-Compound-2 + MK-4827 DCOLC5B PMID28460551-Compound-2 Malignant melanoma (Cell Line: RPMI7951) [5]
PMID28460551-Compound-2 + MK-4827 DCZ1JTT PMID28460551-Compound-2 Malignant melanoma (Cell Line: SKMEL30) [5]
PMID28460551-Compound-2 + MK-4827 DCEFP0M PMID28460551-Compound-2 Mesothelioma (Cell Line: MSTO) [5]
PMID28460551-Compound-2 + MK-4827 DCV3LX2 PMID28460551-Compound-2 Non small cell carcinoma (Cell Line: SKMES1) [5]
PMID28460551-Compound-2 + MK-4827 DC2QHWU PMID28460551-Compound-2 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
PMID28460551-Compound-2 + MK-4827 DCAEXVO PMID28460551-Compound-2 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
PMID28460551-Compound-2 + MK-4827 DC4OTAT PMID28460551-Compound-2 Prostate carcinoma (Cell Line: LNCAP) [5]
PMID28460551-Compound-2 + MK-4827 DCJ35LH PMID28460551-Compound-2 Prostate carcinoma (Cell Line: VCAP) [5]
SCH 727965 + MK-4827 DCO7WUL SCH 727965 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
SCH 727965 + MK-4827 DC7N05K SCH 727965 Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
SCH 727965 + MK-4827 DCLGDG3 SCH 727965 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
SCH 727965 + MK-4827 DCNWV2J SCH 727965 Breast carcinoma (Cell Line: ZR751) [4]
SCH 727965 + MK-4827 DCA24FU SCH 727965 Breast carcinoma (Cell Line: KPL1) [4]
SCH 727965 + MK-4827 DC697WH SCH 727965 Breast carcinoma (Cell Line: OCUBM) [4]
SCH 727965 + MK-4827 DC0HB0P SCH 727965 Carcinoma (Cell Line: EFM192B) [4]
SCH 727965 + MK-4827 DCW1ILJ SCH 727965 Carcinoma (Cell Line: MDAMB436) [4]
SCH 727965 + MK-4827 DCMZKFN SCH 727965 Colon adenocarcinoma (Cell Line: LOVO) [4]
SCH 727965 + MK-4827 DCXSUXF SCH 727965 Colon carcinoma (Cell Line: RKO) [4]
SCH 727965 + MK-4827 DCEGW23 SCH 727965 Invasive ductal carcinoma (Cell Line: T-47D) [4]
SCH 727965 + MK-4827 DC696X1 SCH 727965 Adenocarcinoma (Cell Line: CAOV3) [5]
SCH 727965 + MK-4827 DC1DDQ1 SCH 727965 Adenocarcinoma (Cell Line: OVCAR3) [5]
SCH 727965 + MK-4827 DCHTTY5 SCH 727965 Adenocarcinoma (Cell Line: A427) [5]
SCH 727965 + MK-4827 DCLPMDM SCH 727965 Adenocarcinoma (Cell Line: NCIH2122) [5]
SCH 727965 + MK-4827 DCD6ULY SCH 727965 Adenocarcinoma (Cell Line: NCIH23) [5]
SCH 727965 + MK-4827 DCQ97H9 SCH 727965 Adenocarcinoma (Cell Line: NCIH520) [5]
SCH 727965 + MK-4827 DCNYKAI SCH 727965 Adenocarcinoma (Cell Line: COLO320DM) [5]
SCH 727965 + MK-4827 DCNDJ48 SCH 727965 Adenocarcinoma (Cell Line: DLD1) [5]
SCH 727965 + MK-4827 DC4LTRP SCH 727965 Adenocarcinoma (Cell Line: HCT116) [5]
SCH 727965 + MK-4827 DCGV3UZ SCH 727965 Adenocarcinoma (Cell Line: HT29) [5]
SCH 727965 + MK-4827 DC82UBL SCH 727965 Adenocarcinoma (Cell Line: SW-620) [5]
SCH 727965 + MK-4827 DC9ZVQB SCH 727965 Amelanotic melanoma (Cell Line: A2058) [5]
SCH 727965 + MK-4827 DC9GIIF SCH 727965 Germ cell tumour (Cell Line: PA1) [5]
SCH 727965 + MK-4827 DC61CRJ SCH 727965 Large cell lung carcinoma (Cell Line: NCI-H460) [5]
SCH 727965 + MK-4827 DCBOLHQ SCH 727965 Malignant melanoma (Cell Line: A375) [5]
SCH 727965 + MK-4827 DCQBEQC SCH 727965 Malignant melanoma (Cell Line: HT144) [5]
SCH 727965 + MK-4827 DCZ1MPD SCH 727965 Malignant melanoma (Cell Line: RPMI7951) [5]
SCH 727965 + MK-4827 DCO3GRW SCH 727965 Malignant melanoma (Cell Line: SKMEL30) [5]
SCH 727965 + MK-4827 DC2DTRI SCH 727965 Malignant melanoma (Cell Line: UACC62) [5]
SCH 727965 + MK-4827 DCEFV8W SCH 727965 Mesothelioma (Cell Line: MSTO) [5]
SCH 727965 + MK-4827 DC7XKKZ SCH 727965 Non small cell carcinoma (Cell Line: SKMES1) [5]
SCH 727965 + MK-4827 DC8ODSZ SCH 727965 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
SCH 727965 + MK-4827 DCPQ91K SCH 727965 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
SCH 727965 + MK-4827 DC0U3H4 SCH 727965 Prostate carcinoma (Cell Line: LNCAP) [5]
SCH 727965 + MK-4827 DCSWNY4 SCH 727965 Prostate carcinoma (Cell Line: VCAP) [5]
Taxol + MK-4827 DCZKYOP Taxol Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
Taxol + MK-4827 DCWCOXW Taxol Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
Taxol + MK-4827 DC87280 Taxol Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
Taxol + MK-4827 DCLGQ69 Taxol Breast carcinoma (Cell Line: KPL1) [4]
Taxol + MK-4827 DCDQW9D Taxol Breast carcinoma (Cell Line: OCUBM) [4]
Taxol + MK-4827 DCI4NAJ Taxol Carcinoma (Cell Line: OV90) [4]
Taxol + MK-4827 DC7OV6C Taxol Carcinoma (Cell Line: EFM192B) [4]
Taxol + MK-4827 DCDF9YY Taxol Colon adenocarcinoma (Cell Line: LOVO) [4]
Taxol + MK-4827 DCXTNRG Taxol Colon carcinoma (Cell Line: RKO) [4]
Taxol + MK-4827 DCYMBDC Taxol Invasive ductal carcinoma (Cell Line: T-47D) [4]
Taxol + MK-4827 DCKBMZY Taxol Rectal adenocarcinoma (Cell Line: SW837) [4]
Taxol + MK-4827 DC59LE0 Taxol Adenocarcinoma (Cell Line: NCIH1650) [5]
Taxol + MK-4827 DCXKUGN Taxol Adenocarcinoma (Cell Line: NCIH520) [5]
Taxol + MK-4827 DCMOP06 Taxol Adenocarcinoma (Cell Line: COLO320DM) [5]
Taxol + MK-4827 DCCZUCO Taxol Adenocarcinoma (Cell Line: DLD1) [5]
Taxol + MK-4827 DCZ8K39 Taxol Adenocarcinoma (Cell Line: HT29) [5]
Taxol + MK-4827 DCWATTV Taxol Adenocarcinoma (Cell Line: SW-620) [5]
Taxol + MK-4827 DCFVW72 Taxol Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Taxol + MK-4827 DCOZWBI Taxol Malignant melanoma (Cell Line: HT144) [5]
Taxol + MK-4827 DCDMG9B Taxol Malignant melanoma (Cell Line: RPMI7951) [5]
Taxol + MK-4827 DCJW27T Taxol Malignant melanoma (Cell Line: SKMEL30) [5]
Taxol + MK-4827 DCX9FK0 Taxol Mesothelioma (Cell Line: MSTO) [5]
Taxol + MK-4827 DCATH9F Taxol Non small cell carcinoma (Cell Line: SKMES1) [5]
Taxol + MK-4827 DC1PCTG Taxol Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
Taxol + MK-4827 DCT41RY Taxol Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Topotecan + MK-4827 DCZMDHY Topotecan Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
Topotecan + MK-4827 DCKOUS6 Topotecan Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
Topotecan + MK-4827 DCII00O Topotecan Breast carcinoma (Cell Line: KPL1) [4]
Topotecan + MK-4827 DCZWDU0 Topotecan Breast carcinoma (Cell Line: OCUBM) [4]
Topotecan + MK-4827 DCVIP3C Topotecan Colon adenocarcinoma (Cell Line: LOVO) [4]
Topotecan + MK-4827 DCNVY2B Topotecan Colon carcinoma (Cell Line: RKO) [4]
Topotecan + MK-4827 DC7MRWM Topotecan Invasive ductal carcinoma (Cell Line: T-47D) [4]
Topotecan + MK-4827 DCDPBVQ Topotecan Rectal adenocarcinoma (Cell Line: SW837) [4]
Topotecan + MK-4827 DCHRF8K Topotecan Adenocarcinoma (Cell Line: CAOV3) [5]
Topotecan + MK-4827 DC70YC5 Topotecan Adenocarcinoma (Cell Line: OVCAR3) [5]
Topotecan + MK-4827 DCV6HWC Topotecan Adenocarcinoma (Cell Line: A427) [5]
Topotecan + MK-4827 DCA3XCY Topotecan Adenocarcinoma (Cell Line: NCIH2122) [5]
Topotecan + MK-4827 DC1XNHI Topotecan Adenocarcinoma (Cell Line: NCIH23) [5]
Topotecan + MK-4827 DCL62JN Topotecan Adenocarcinoma (Cell Line: NCIH520) [5]
Topotecan + MK-4827 DCM6JTJ Topotecan Adenocarcinoma (Cell Line: COLO320DM) [5]
Topotecan + MK-4827 DCANWEH Topotecan Adenocarcinoma (Cell Line: DLD1) [5]
Topotecan + MK-4827 DCZHVBI Topotecan Adenocarcinoma (Cell Line: HCT116) [5]
Topotecan + MK-4827 DCMY6O1 Topotecan Adenocarcinoma (Cell Line: HT29) [5]
Topotecan + MK-4827 DCC0Y4E Topotecan Adenocarcinoma (Cell Line: SW-620) [5]
Topotecan + MK-4827 DC9NSG0 Topotecan Amelanotic melanoma (Cell Line: A2058) [5]
Topotecan + MK-4827 DCDELN2 Topotecan Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [5]
Topotecan + MK-4827 DCUJ0HD Topotecan Germ cell tumour (Cell Line: PA1) [5]
Topotecan + MK-4827 DCBYEW7 Topotecan Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Topotecan + MK-4827 DCRJ694 Topotecan Malignant melanoma (Cell Line: A375) [5]
Topotecan + MK-4827 DCEXYGY Topotecan Malignant melanoma (Cell Line: SKMEL30) [5]
Topotecan + MK-4827 DCR4J4O Topotecan Non small cell carcinoma (Cell Line: SKMES1) [5]
Topotecan + MK-4827 DCZ1MSP Topotecan Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
Topotecan + MK-4827 DCC4PTS Topotecan Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Topotecan + MK-4827 DCEV2HU Topotecan Prostate carcinoma (Cell Line: LNCAP) [5]
Topotecan + MK-4827 DCYF19E Topotecan Prostate carcinoma (Cell Line: VCAP) [5]
Vinblastine + MK-4827 DCR57DF Vinblastine Adenocarcinoma (Cell Line: OVCAR3) [3]
Vinblastine + MK-4827 DC5922K Vinblastine Adenocarcinoma (Cell Line: COLO320DM) [3]
Vinblastine + MK-4827 DC6P88M Vinblastine Adenocarcinoma (Cell Line: DLD1) [3]
Vinblastine + MK-4827 DC8HHT6 Vinblastine Amelanotic melanoma (Cell Line: A2058) [3]
Vinblastine + MK-4827 DC8VAVU Vinblastine Germ cell tumour (Cell Line: PA1) [3]
Vinblastine + MK-4827 DCGO38J Vinblastine Malignant melanoma (Cell Line: HT144) [3]
Vinblastine + MK-4827 DCNDRJA Vinblastine Malignant melanoma (Cell Line: RPMI7951) [3]
Vinblastine + MK-4827 DC27KSU Vinblastine Malignant melanoma (Cell Line: SKMEL30) [3]
Vinblastine + MK-4827 DCMVI6G Vinblastine Malignant melanoma (Cell Line: UACC62) [3]
Vinblastine + MK-4827 DC2L8D0 Vinblastine Mesothelioma (Cell Line: MSTO) [3]
Vinblastine + MK-4827 DC2MOXN Vinblastine Non small cell carcinoma (Cell Line: SKMES1) [3]
Vinblastine + MK-4827 DC3J1UQ Vinblastine Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [3]
Vinblastine + MK-4827 DCF5FV4 Vinblastine Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
Vinblastine + MK-4827 DCM4K55 Vinblastine Prostate carcinoma (Cell Line: LNCAP) [3]
Vinblastine + MK-4827 DCS4DWM Vinblastine Prostate carcinoma (Cell Line: VCAP) [3]
Vinblastine + MK-4827 DC08GXQ Vinblastine Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
Vinblastine + MK-4827 DCXTXTJ Vinblastine Breast carcinoma (Cell Line: KPL1) [4]
Vinblastine + MK-4827 DC2Q86I Vinblastine Breast carcinoma (Cell Line: OCUBM) [4]
Vinblastine + MK-4827 DCD635T Vinblastine Carcinoma (Cell Line: OV90) [4]
Vinblastine + MK-4827 DCF7KOL Vinblastine Carcinoma (Cell Line: EFM192B) [4]
Vinblastine + MK-4827 DCGPVX8 Vinblastine Carcinoma (Cell Line: MDAMB436) [4]
Vinblastine + MK-4827 DCVQ6ZG Vinblastine Colon adenocarcinoma (Cell Line: LOVO) [4]
Vinblastine + MK-4827 DCWYHPM Vinblastine Colon carcinoma (Cell Line: RKO) [4]
Vinblastine + MK-4827 DC1M4FQ Vinblastine Invasive ductal carcinoma (Cell Line: T-47D) [4]
Vinblastine + MK-4827 DCBY76X Vinblastine Rectal adenocarcinoma (Cell Line: SW837) [4]
Vinorelbine + MK-4827 DCSVNM0 Vinorelbine Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
Vinorelbine + MK-4827 DC1C3VF Vinorelbine Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
Vinorelbine + MK-4827 DCQ6LSR Vinorelbine Breast carcinoma (Cell Line: KPL1) [4]
Vinorelbine + MK-4827 DCERZHW Vinorelbine Breast carcinoma (Cell Line: OCUBM) [4]
Vinorelbine + MK-4827 DCHZQGL Vinorelbine Carcinoma (Cell Line: OV90) [4]
Vinorelbine + MK-4827 DCSMI3Q Vinorelbine Carcinoma (Cell Line: EFM192B) [4]
Vinorelbine + MK-4827 DC04C30 Vinorelbine Colon adenocarcinoma (Cell Line: LOVO) [4]
Vinorelbine + MK-4827 DCVOPC2 Vinorelbine Colon carcinoma (Cell Line: RKO) [4]
Vinorelbine + MK-4827 DCMVKO8 Vinorelbine Invasive ductal carcinoma (Cell Line: T-47D) [4]
Vinorelbine + MK-4827 DCFU6XM Vinorelbine Rectal adenocarcinoma (Cell Line: SW837) [4]
Vinorelbine + MK-4827 DCS41WW Vinorelbine Adenocarcinoma (Cell Line: NCIH1650) [5]
Vinorelbine + MK-4827 DCR2ZR4 Vinorelbine Adenocarcinoma (Cell Line: NCIH520) [5]
Vinorelbine + MK-4827 DCIBRTN Vinorelbine Adenocarcinoma (Cell Line: COLO320DM) [5]
Vinorelbine + MK-4827 DCV6A07 Vinorelbine Adenocarcinoma (Cell Line: DLD1) [5]
Vinorelbine + MK-4827 DCHGUSB Vinorelbine Adenocarcinoma (Cell Line: HT29) [5]
Vinorelbine + MK-4827 DCGOMQV Vinorelbine Adenocarcinoma (Cell Line: SW-620) [5]
Vinorelbine + MK-4827 DCHOXZ7 Vinorelbine Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [5]
Vinorelbine + MK-4827 DCU4KVY Vinorelbine Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Vinorelbine + MK-4827 DCZE4K9 Vinorelbine Malignant melanoma (Cell Line: RPMI7951) [5]
Vinorelbine + MK-4827 DCU28TH Vinorelbine Malignant melanoma (Cell Line: SKMEL30) [5]
Vinorelbine + MK-4827 DCB5IEW Vinorelbine Mesothelioma (Cell Line: MSTO) [5]
Vinorelbine + MK-4827 DCYKNJH Vinorelbine Non small cell carcinoma (Cell Line: SKMES1) [5]
Vinorelbine + MK-4827 DCVBP23 Vinorelbine Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
Vinorelbine + MK-4827 DCDMU19 Vinorelbine Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
------------------------------------------------------------------------------------
⏷ Show the Full List of 893 DrugCom(s)
16 Clinical Trial Drug Combination(s) Consisting of This drug
DrugCom Name DrugCom ID Component Drug Indication REF
Al3818 + MK-4827 DCSZQXT Al3818 HER2-negative Breast Cancer [6]
Brivanib + MK-4827 DCQK8TH Brivanib Ovarian Cancer [7]
Carboplatin + MK-4827 DCGTJC1 Carboplatin Solid Tumor, Adult [8]
Cotellic + MK-4827 DCLCOR5 Cotellic OVARIAN CANCER [9]
Enzalutamide + MK-4827 DC5F66S Enzalutamide Metastatic Prostate Cancer [10]
Everolimus + MK-4827 DC5LC1P Everolimus Breast Cancer [11]
HKI-272 + MK-4827 DC1A4BV HKI-272 Advanced Solid Tumor [12]
LY2835219 + MK-4827 DCCFYMI LY2835219 Anatomic Stage I Breast Cancer AJCC v8 [13]
MK-4827 + Irinotecan DC01Y4T Irinotecan Metastatic Solid Tumor [14]
MK-4827 + Irinotecan DCN401R Irinotecan Ewing Sarcoma [15]
MK-4827 + Osimertinib DCNCXJ9 Osimertinib Lung Cancer [16]
Temozolomide + MK-4827 DCSFJRJ Temozolomide Recurrence of Solid Tumor [17]
Temozolomide + MK-4827 DCVU19I Temozolomide Ewing Sarcoma [15]
Temozolomide + MK-4827 DC0YERE Temozolomide Glioma, Malignant [18]
Al3818 + MK-4827 DCW428S Al3818 Platinum-resistant Ovarian Cancer [19]
Fulvestrant + MK-4827 DCVL6DQ Fulvestrant Breast Cancer [20]
------------------------------------------------------------------------------------
⏷ Show the Full List of 16 DrugCom(s)

References

1 ClinicalTrials.gov (NCT03602859) A Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer (FIRST). U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
4 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
5 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
6 ClinicalTrials.gov (NCT04764084) Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid Tumors
7 ClinicalTrials.gov (NCT03895788) A Study of Niraparib in Combination With Brivanib in Recurrent Ovarian Cancer
8 ClinicalTrials.gov (NCT03209401) Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor Malignancies
9 ClinicalTrials.gov (NCT03695380) A Clinical Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab to Patients With Advanced Platinum-sensitive Ovarian Cancer
10 ClinicalTrials.gov (NCT02500901) Enzalutamide and Niraparib in the Treatment of Metastatic Castrate-Resistant Prostate Cancer (CRPC)
11 ClinicalTrials.gov (NCT03154281) Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Advanced Gynecologic Malignancies and Breast
12 ClinicalTrials.gov (NCT04502602) Niraparib and Neratinib in Advanced Solid Tumors With Expansion Cohort in Advanced Ovarian Cancer
13 ClinicalTrials.gov (NCT04481113) Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer
14 ClinicalTrials.gov (NCT05694715) Combination Therapy in Cancers With Mutations in DNA Repair Genes
15 ClinicalTrials.gov (NCT02044120) ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide and/or Irinotecan Patients With Previously Treated, Incurable Ewing Sarcoma
16 ClinicalTrials.gov (NCT03891615) Niraparib in Combination With Osimertinib in EGFR-Mutated Advanced Lung Cancer
17 ClinicalTrials.gov (NCT01294735) Study of the Safety and Efficacy of MK-4827 Given With Temozolomide in Participants With Advanced Cancer (MK-4827-014 AM1)
18 ClinicalTrials.gov (NCT06258018) Niraparib and Temozolomide in Patients Glioblastoma
19 ClinicalTrials.gov (NCT04376073) Anlotinib and Niraparib Dual Therapy Evaluation in Platinum-resistant Recurrent Ovarian Cancer
20 ClinicalTrials.gov (NCT05601440) Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer